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ABSTRACT 
Physiological changes that occur with aging affect the pharmacokinetics and 
pharmacodynamics of drugs. The elderly often suffer from more diseases simultaneously and 
thus consume more concomitant prescription medications. Polypharmacy may consequently 
result with greater health care costs, medication non-adherence, an increased risk of adverse 
drug reactions, potential drug-drug interactions and potentially inappropriate medications` use. 
Our goal was to determine the prevalence of potential drug-drug interactions and potentially 
inappropriate medications among geriatric patients who were treated at the Department of 
Cardiology in Pula General Hospital. In the retrospective study we included the first 100 
patients 65 years old and above who were admitted to cardiology department from September 
1
st
 2016 onwards and who had at least 2 chronic systemic medications prescribed at the 
moment of their admission. All the data were obtained from the Hospital Information System 
program. For detecting potential drug-drug interactions we used Lexi-Interact Online
TM
 (only 
interactions of types D and X) and potentially inappropriate medications in the elderly were 
identified using the last updated version of Beers criteria.  
In our group of patients (average age 78.2 years, 57 % women) the median number of 
medications used per patient was 7, which is considered as high polypharmacy. The number of 
prescription medications was decreasing with the increasing age of the patients. Three most 
often used chronic systemic prescription medications were furosemide, pantoprazole and 
bisoprolol. 49 % of patients were exposed to at least one potential drug-drug interaction and 
61 % of them had at least one potentially inappropriate medication in their regular therapy. 
Drugs most often involved in potential drug-drug interactions of type D were clopidogrel, 
warfarin and allopurinol, while the interactions of type X mostly included potassium salts, 
anticholinergics and antipsychotics. Most frequent potentially inappropriate medications were 
pantoprazole, diazepam and amiodarone. Pharmacotherapy in the elderly could be improved 
by introducing pharmacist cognitive services such as medicine use review and advanced 
medication review in Croatian health care institutions. 
KEY WORDS: elderly, polypharmacy, drug-drug interactions, potentially inappropriate 
medications, Beers criteria 
RAZŠIRJEN POVZETEK 
Uvod: S staranjem začnejo pri starostnikih upadati fiziološke funkcije, kar lahko pripelje do 
pogostejše obolevnosti ter s tem tudi do uporabe več zdravil hkrati. Fiziološke spremembe pri 
njih vplivajo na spremenjeno farmakokinetiko in farmakodinamiko zdravil. Med 
farmakokinetičnimi procesi so pri starostnikih zaznane spremembe na nivoju absorpcije, 
porazdelitve, metabolizma in izločanja zdravil, medtem ko se farmakodinamčne spremembe 
lahko pokažejo na nivoju receptorjev, prevajanja signalov ali homeostatskih mehanizmov. 
Posledično pride pogosteje do pojava neželenih učinkov zdravil. Več sočasnih obolenj pri 
starostnikih vodi v polifarmakoterapijo, ki lahko ima za posledico veliko neželenih izidov, kot 
so neželeni učinki zdravil, slabo sodelovanje pacientov pri zdravljenju z zdravili, veliki stroški 
zdravljenja ter pogostejši pojav klinično pomembnih interakcij med zdravili ali celo uporabo 
potencialno neprimernih zdravil za starostnike. Danes je na voljo precej informacijskih 
sistemov, ki omogočajo varnejše in bolj racionalno predpisovanje zdravil pri starostnikih. 
Vendar je vedno potrebno upoštevati, da so vsa opozorila in priporočila za varno 
predpisovanje samo potencialna. Vsak pacient je individualen in njegovo zdravljenje je močno 
odvisno od obstoječih bolezni, njegovega splošnega zdravstvenega stanja, življenskih navad 
ter sočasne uporabe zdravil brez recepta in prehranskih dopolnil. 
  
Namen: Pri starostnikih, ki so se zdravili na kardiološkem oddelku Splošne bolnišnice Pulj, 
smo želeli retrospektivno določiti pogostost potencialnih interakcij med sistemsko kronično 
terapijo, ki so jo prejemali ob sprejemu v bolnišnico ter ustreznost predpisanih zdravil glede 
na Beersove kriterije. 
 
Metode: Z vključevanjem bolnikov smo začeli 1. septembra 2016 in vključili prvih 100 
bolnikov starih 65 in več let, ki so se zdravili na kardiološkem oddelku ter so ob sprejemu v 
bolnišnico imeli predpisani vsaj dve kronični sistemski zdravili. Podatke o bolnikih in njihovi 
farmakoterapiji smo pridobili s pomočjo bolnišnično informacijskega sistema BIS, ki je 
namenjen shranjevanju in avtomatizaciji vseh kliničnih podatkov o pacientih. Potencialne 
interakcije med zdravili smo preverjali s pomočjo Lexi-Interact
TM 
Online. To je podatkovna 
baza namenjena identifikaciji neprimernih kombinacij zdravil in zdravilnih rastlin, ki je 
ustvarjena na podlagi različnih znanstevnih virov in strokovne literature. V tej bazi so 
 
 
interakcije med zdravili razdeljene v 5 kategorij glede klinične pomembnosti. Za potrebe naše 
raziskave smo se osredotočili samo na klinično pomembne interakcije tipa D (priporoča se 
zamenjava terapije) in X (kombinacija je kontraindicirana). Za identifikacijo potencialno 
neprimernih zdravil pri starostnikih smo uporabljali Beersove kriterije, ki so jih prvič objavili 
leta 1991. Njihov namen je bil zmanjšati incidenco neželenih učinkov zdravil pri starostnikih v 
Združenih Državah Amerike, danes pa se ti kriteriji uporabljajo povsod po svetu. V raziskavi 
smo uporabili zadnjo posodobljeno verzijo iz leta 2015 in sicer predvsem tabeli 2 in 3. Tabela 
2 je sestavljena iz zdravilnih učinkovin ali njihovih skupin, ki naj bi bile neprimerne za 
uporabo pri starostnikih, v tabeli 3 pa so zdravilne učinkovine, ki so neprimerne za uporabo 
pri starostnikih le pri določenih bolezenskih stanjih. Pri vsaki posamezni zdravilni učinkovini 
oz. skupini zdravilnih učinkovin, ki niso primerne za uporabo pri starostnikih, je tudi razlaga 
in priporočilo za obravnavo, podprto z medicinskimi dokazi. 
 
Rezultati: V raziskavo smo vključili 100 pacientov, z mediano starosti 78 let. Največ 
pacientov (53 %) je bilo starih med 75 in 84 let. Več kot polovico (57 %) so bile ženske. 
Bolečina v prsih in dispneja sta bila dva najpogostejša razloga za hospitalizacijo, medtem ko 
je bila arterijska hipertenzija najpogostejše kronično obolenje. Mediana kroničnih bolezni na 
pacienta je bila 4. Izkazalo se je, da so najstarejši med našimi pacienti imeli najmanjše število 
kroničnih bolezni. Mediana kroničnih sistemskih zdravil na recept je bila 7 na pacienta. 
Pacient z največjim številom zdravil je imel predpisanih celo 19 kroničnih zdravil. Ugotovili 
smo tudi to, da je najmlajša skupina pacientov (65-74 let) jemala največ zdravil. 60 % 
pacientov je imelo več kot 5 predpisanih kroničnih zdravil, kar pomeni, da so bili podvrženi 
polifarmakoterapiji. Najpogosteje predpisana zdravila so bila iz terapevtskih skupin C, A in N 
po ATC klasifikacijskem sistemu, medtem ko so bile najpogosteje predpisane zdravilne 
učinkovine furosemid, pantoprazol in bisoprolol. Pri 49 % pacientov smo detektirali vsaj eno 
potencialno interakcijo med zdravili. Rezultati so pokazali, da je incidenca potencialnih 
interakcij naraščala z naraščujočim številom predpisanih zdravil, saj je le-ta bila 61,5 % pri 
bolnikom, ki so jemali od 6 do 10 zdravil, ter skoraj 100 % pri tistih ki so imeli več kot 10 
sočasno predpisanih zdravil. Med pacienti z interakcijami je bila mediana interakcij na bolnika 
2. Samo interakcije tipa D so bile detektirane pri 38 % bolnikov, medtem ko smo samo X 
interakcije zasledili pri 3 % pacientov. D in X interakcije je imelo sočasno v svoji kronični 
 
 
terapiji 8 % pacientov. Zdravila, ki so bila najpogosteje vključena v interakcije tipa D so iz 
terapevtskih skupin C, N in A, medtem ko so v X interakcije največkrat vstopala zdravila iz 
skupin N in R. V interakcijah tipa D so bile najpogosteje identificirane učinkovine varfarin, 
klopidogrel in alopurinol, v interakcije tipa X pa so bile pogosto vključene kalijeve soli. 61 % 
pacientov je redno jemalo vsaj eno neprimerno zdravilo za starostnike, kar se je v primerjavi s 
podobnimi raziskavami izkazalo kot precej visok rezultat. Mediana potencialno neprimernih 
zdravil na pacienta je znašala 1. Ena pacientka v raziskavi je sočasno jemala celo 4 
potencialno neprimerna zdravila. Pacienti, ki so imeli več predpisanih zdravil, so imeli tudi 
večjo mediano potencialno neprimernih zdravil za starostnike. Najpogostejša predpisana 
neprimerna zdravila za starostnike so bila pantoprazol, diazepam in amiodaron. 
 
Sklep: Pogostost potencialnih interakcij med zdravili kot tudi potencialno neprimernih zdravil 
za starostnike se je pri naših pacientih izkazala za zelo visoko. Moramo pa poudariti, da so vse 
interakcije in neprimerna zdravila samo potencialna in da ni nujno, da se negativni izidi le-teh 
vedno klinično izrazijo. Za pridobitev natančnejših rezultatov bi bilo bolj primerno narediti 
prospektivno študijo, saj bi na ta način lahko pridobili bolj zanesljivo zgodovino zdravljenja z 
zdravili ter hkrati ugotavljali, ali so se posledice neprimernega predpisovanja zdravil dejansko 
izrazile pri pacientih. Pri optimizaciji farmakoterapije pri starostnikih in tudi na splošno imajo 
ključno vlogo klinični farmacevti, ki žal še niso popolnoma integrirani v zdravstvene 
inštitucije na Hrvaškem. Z uvajanjem farmacevtskih kognitivnih storitev, kot so pregled 
uporabe zdravil in farmakoterapijski pregled, bi se optimizacija in racionalizacija zdravljenja z 
zdravili lahko izboljšala. S tem bi lahko zmanjšali neželene učinke zdravil, 
polifarmakoterapijo, interakcije med zdravili ter tudi breme zdravstvenega zavarovanja. 
Zaenkrat imajo velik pomen farmacevti v javnih lekarnah, saj lahko detektirajo in ukrepajo pri 
težavah povezanih z zdravili, ter na ta način izboljšajo uporabo zdravil, še posebej pri 
starostnikih.  
 
KLJUČNE BESEDE: starostniki, polifarmakoterapija, interakcije med zdravili, potencialno 
neprimerna zdravila za starostnike, klinična farmacija 
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1. INTRODUCTION 
The definition of the elderly usually comprises of chronological ages of 65 years or older (1). 
Due to a higher life standards and advances in medicine, societies are now faced with a large 
aging population. The World Health Organization (WHO) predicts that the number of geriatric 
population will double by 2050. Those aged 80 years or more will number 400 million persons 
(2). In Croatia, for example, 19.4 % of inhabitants were aged 65 or more years back in 2016. 
By the year 2050 more than 30 % of the population is expected to be a part of this group (3).  
1.1. AGING 
Aging is defined as a series of anatomical and physiological changes that consider reduced 
physiological functions and weakened homeostatic reserve (4). An organism is gradually 
declining in its performing and structural functions, resulting with an increased risk of disease, 
impairment, and mortality (5). 
1.1.1. PHYSIOLOGICAL CHANGES IN THE ELDERLY 
Age-related physiological changes occur in all organ systems and play an important role in the 
clinical management of elderly patients (6). 
The most notable changes in the central nervous system that are associated with senescence 
are reduced number of brain cells and a decrease in the brain blood flow (6). Cardiovascular 
system changes occur mostly in cardiac output and heart frequency, since these were shown to 
recede linearly with age. Enhanced peripheral vascular resistance results with higher diastolic 
and systolic arterial blood pressure, as well as with an increased afterload of the heart (6). 
Regarding the respiratory system, the reduction of vital capacity is found to be present in the 
older adults. Maximum voluntary ventilation, forced expiratory volume in one second, and 
maximal expiratory flow rate decrease by 30 % (6). The senescence also brings gradual 
decreases in the genitourinary system. The volume and weight of the kidneys reduce, as well 
as the blood flow through them. Furthermore, there is a notable fall in the total number of 
glomeruli in each kidney and thereby a decrease in the creatinine clearance and glomerular 
filtration. Enlargement of the prostate occurs in most older men and the capacity of the bladder 
decreases in both sexes (6). Aging has an impact on the gastrointestinal tract (GIT) as well, 
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considering the diminution of intestinal motility and intestinal blood flow. The colon becomes 
hypotonic, which leads to the enhanced storage capacity and longer stool transit time. An 
increase in the gastric pH leads to decreased gastric acid excretion (6). The liver, which is 
responsible for the metabolism of most drugs, decreases in weight by 20 % after the age of 50, 
and so does the liver blood flow. Senescence also brings a progressive impairment in the 
number and the function of insulin producing beta cells, which results with an enlarged 
concentration of blood glucose (6). The elderly lose body water and gain in body fat. A 
relative decrease in lean body mass is a result of loss and atrophy of muscle cells. The bone 
mass is also reduced. Dermal collagen becomes stiffer and elastin has a higher degree of 
calcification, resulting in loss of skin tone and elasticity, t.i. sagging and wrinkling (6). 
Pharmacokinetics and pharmacodynamics of drugs get affected by the age-associated 
physiological changes, which is why absorption, distribution, metabolism and elimination in 
the elderly are changed, as well as the effect of a drug on its target site (7). In order to avoid 
potential adverse drug reactions (ADR) a rationale and circumspective prescribing of 
medications in older adults should be, therefore, always applied. 
1.1.2. THE CHANGES OF PHARMACOKINETICS IN THE ELDERLY 
 ABSORPTION 
Earlier studies reported that slowed gastric acid secretion and an elevation in its pH value, as 
well as the reduction in the intestinal motility, blood flow to gut, and absorption of small 
intestine, decrease drug absorption (8, 9). But, latest reports have not confirmed these findings 
in healthy subjects, since they did not manage to prove the decreased absorption of 
paracetamol, acetylsalicylic acid (ASA) and lorazepam in those subjects (10). 
 DISTRIBUTION 
Drug distribution is due to many physiological changes reduced in the elderly. Age-related 
decrease in serum albumin concentration may result in higher pharmacological activity of 
drugs, while increase in α-1-acid glycoprotein concentrations could bring to reduced response 
to basic drugs (eg. allopurinol, diazepam). Although, it seems these effects do not occur in the 
healthy subjects (10). Altered drug distribution, that is a consequence of changed plasma 
protein concentrations, is usually associated with co-morbidities rather than the old age. 
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Distribution volume of hydrophilic drugs (eg. teophylline, digoxin, ASA) is lower due to the 
reduction in total body water. Increase in body fat, on the other hand, enhances distribution 
volume and biological half-life of lipophilic drugs, as are diazepam and amiodarone (10). 
 METABOLISM 
Drug metabolism and biotransformation mainly take place in the liver. With aging the liver 
mass reduces and hepatic blood flow decreases by about 30 % (11). Therefore, drugs with 
high intrinsic clearance (verapamil, propranolol) and low capability of binding to plasma 
proteins are heavily dependent on the hepatic blood flow and are expected to have an altered 
metabolism (10). Metabolism in the liver runs in two phases. The phase I considers reactions 
of oxidation, reduction and hydrolysis mostly supported by cytochrome P450 (CYP) enzymes 
catalyzation. Here the drugs are turned into more polar compounds. In the elderly this pathway 
is expected to be slower. Some studies have shown that the reason for it may be reduced 
enzyme activity, but some reports claim that decreased hepatic blood flow is again likely to be 
a factor of diminished velocity of reactions. Phase II reactions (conjugation) involve additions 
of new groups (e.g. acetyl, sulfate, glucuronic acid) and further increase in drugs` polarity. 
This pathway stays unchanged in the older age (10). 
 EXCRETION 
Drug excretion takes place mainly in the kidneys by glomerular filtration or tubular secretion. 
With aging these functions alter because of the reduced mass of kidneys and decreased blood 
flow through them. But some newer studies have shown that these changes do not appear in 
healthy subjects (10). Of particular concern are geriatric patients with co-morbidities such as 
arterial hypertension (AH), diabetes mellitus type 2 (DM 2) or heart failure, since these 
conditions contribute to decreased renal functions and often lead to chronic kidney disease. 
Also, the use of nephrotoxic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), 
as well as frailty syndrome can additionally contribute to decreased elimination of drugs 
through kidneys (10).  
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1.1.3. THE CHANGES OF PHARMACDYNAMICS IN THE ELDERLY 
Altered receptor number, receptor affinity and homeostatic mechanisms are assumed to be the 
main reasons for changes of drugs` pharmacodynamics in the elderly, and consequently 
differed drug effects. Most of the studies regarding pharmacodynamic changes in older 
population were based on drugs with the impact on the central nervous system (CNS) and 
cardiovascular system (10). With aging brain mass and brain blood flow decrease. The result 
is reduced number of neurons and receptors in this area, which makes the elderly more 
susceptible for delirium, extrapyramidal symptoms, arrhythmias, and postural hypotension that 
are often caused by the neuroleptics (7, 10). Aging is also associated with an increased 
sensitivity to the central nervous system impact of benzodiazepines (BZDs). Often 
consequences of chronic administration may be exceeded sedation, confusion and cognitive 
impairments (10). Sedation by diazepam is induced already at lower doses, and an increased 
sensitivity to the effects of nitrazepam, flurazepam, and loprazolam may also be of a great 
concern. All of this could lead to falls and fractures, which are known to be very dangerous in 
the older patients (7). The possible mechanism contributing to altered response to BZDs is 
change in the structure and a number of gamma-aminobutyric acid (GABA) receptors. Other 
suggested explanation is altered distribution of BZDs to the CNS in the elderly. Besides that, 
older patients` dopaminergic and cholinergic system activity is also declined, which may 
result in the enhanced response to antidepressants and a greater risk of extrapyramidal 
symptoms if using antipsychotics (10). Regarding the cardiovascular system age-associated 
changes indicate decrease in baroreceptor reflex response, drops in blood pressure, and 
consequently an increase in the incidence of orthostasis. Also, aging is associated with a 
decreased response to both β-adrenergic agonists and antagonists. They are considered less 
effective in elderly patients in comparison with other antihypertensive agents (7). That may 
also affect the respiratory system, since the responsiveness to drugs such as salbutamol (β-
adrenoceptor agonist) and propranolol (β-adrenoceptor antagonist) reduces with age. The 
responsiveness of α-adrenoceptors, on the other hand, stays unchanged (7). The renin-
angiotensin-aldosterone system (RAAS) activity is declined by the decreased production of 
renin and aldosterone. The result is altered responsiveness to diuretics. However, 
responsiveness to angiotensin-converting-enzyme inhibitors (ACEIs) stays unchanged in the 
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elderly. Aging also brings reduction in albumin concentrations. Thus, loop diuretics such as 
furosemide, that have a high affinity for albumin are expected to have decreased effect (12). 
The risk for atrial fibrillation (AF) as well as for stroke increases with aging. But so does the 
possibility for thrombosis and hemorrhage when on the anticoagulant therapy. Thus, the 
prevention of mentioned conditions present a great challenge in the elderly (10). Not many 
studies on effect of warfarin in the elderly have been conducted, but the possible mechanisms 
may be the infrequent vitamin K reach food intake, its lower absorption or altered capacity in 
the synthesis of coagulation factors. Besides that, elderly are prone to use chronically the 
medications with the influence on the warfarin`s effect, such as amiodarone, NSAIDs, statins, 
selective serotonin reuptake inhibitors (SSRIs), etc (10). 
1.2. POLYPHARMACY IN THE ELDERLY 
Medication prescribing in elderly patients is often challenging for many clinicians. Older 
adults are prone to suffering from multiple diseases at the same time, which is called 
multimorbidity. Numerous co-morbidities often lead to polypharmacy (13). Polypharmacy, 
defined as the use of multiple drugs, is a growing concern for the elderly. According to study 
conducted in the Netherlands (14) we differ between low, moderate and high polypharmacy. 
Low polypharmacy is defined as a long term use of two to three medications at the same time 
per patient. Moderate polypharmacy includes four to five medications per patient, and high 
polypharmacy means more than five concomitantly prescribed medications (14). In 2004 one 
study determined an average of 7 concomitant prescription medications per older patient in 
Croatia. An increase of 65 % was shown regarding the use of prescription medications in the 
12-year period from 2000 to 2012 (15). A study conducted in Slovenia which included 
geriatric patients from nursing homes showed that 50.6 % of patients take more than 6 drugs 
concomitantly (16). In 2016, 50.8 % of all prescribed medications in Slovenia was prescribed 
to patients older than 65 years (13). According to the latest study that evaluated the prevalence 
of polypharmacy in older adults across 17 European countries, Croatia (27.3 %) and Slovenia 
(28.1 %) resulted to be among those with the lowest results (overall range 26.3 % - 39.9 %). 
The sample included individuals aged 65 years or above who took 5 or more concomitant 
medications (17). Polypharmacy may result in many negative consequences. Taking multiple 
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medications at the same time has been associated with greater health care costs, medication 
non-adherence, an increased risk of ADR, reduced functional capacity, but also with potential 
drug-drug interactions (DDIs) and potentially inappropriate medications (PIMs) in the elderly 
(18). 
1.2.1. DRUG-DRUG INTERACTIONS IN THE ELDERLY 
Elderly patients are more susceptible to multiple chronic conditions and consequent use of 
more prescription medications. As the number of concomitantly used medications increases, 
so does the risk of DDIs. Age-associated physiologic changes affect the pharmacokinetic and 
pharmacodynamic of many drugs and enhance the risk of possible DDIs that may cause life-
threatening consequences in the elderly (19). 
There are two categories of DDI mechanisms - pharmacokinetic and pharmacodynamic. 
1.2.1.1. PHARMACOKINETIC DRUG-DRUG INTERACTIONS 
Pharmacokinetic interactions are consequence of alterations in drug absorption, distribution, 
metabolism, and elimination that occur in older adults (20). 
 INTERACTIONS AFFECTING DRUG ABSORPTION 
Alteration of gastrointestinal pH: Some drugs pass through mucosa membranes by simple 
passive diffusion in the non-ionized lipid-soluble form. Therefore, drugs such as H2-
antagonists (ranitidine, famotidine and cimetidine) or proton-pump inhibitors (PPIs) 
pantoprazole, omeprazole, rabeprazole and lansoprazole, that decrease acid production and 
subsequently change the gastric pH, may decrease the absorption of concomitant acidic drugs 
such as salicylic acid (20). 
Formation of complexes: Tetracycline antibacterials are known to interact with di- or trivalent 
metallic ions (Al
3+
, Ca
2+
, Mg
2+
, Bi
2+
 and Zn
2+
) from antacids or dairy products. Tetracycline 
absorption and its antibacterial effects are therefore decreased due to forming insoluble chelate 
complexes with the mentioned ions. The effects of this type of interaction may be reduced if 
the dosages are separated by 2 to 3 hours (20). 
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Changes in gastrointestinal motility: Drugs with antimuscarinic effect can slow the 
gastrointestinal motility and delay the stomach emptying. Thus, anticholinergics, tricyclic 
antidepressants and antipsychotics can retard the absorption of some drugs such as 
paracetamol (20). 
 DRUG DISTRIBUTION INTERACTIONS 
Protein-binding interactions: After entering the systemic circulation, drugs normally bind to 
plasma proteins, but with different extent. Most of the drugs bind to albumins. The portion of 
a drug that remains unbound is pharmacologically active. Many drugs, depending on their 
concentrations and relative affinities for the binding sites, compete with another and replace it 
on the occupied sites (20). 
Induction or inhibition of drug transport proteins: Distribution of drugs into the brain is 
controlled by the action of drug transporter P-glycoprotein. This protein actively transports 
drugs outside the cells once they have entered with passive diffusion. Drugs that are inhibitors 
of this transporter could therefore increase the uptake of drug substrates into the brain, and 
result in an increased possibility for ADR on the CNS (20). 
 DRUG METABOLISM INTERACTIONS 
Enzyme induction: The greatest proportion of drug metabolism is carried out by the CYP 
enzymes from the liver cells. Specific isoforms CYP2C9, CYP2C19, CYP2D6, CYP2E1 and 
CYP3A4 appear to be responsible for about 90 % of the metabolisms of the frequently used 
drugs (20). Among the most clinically important inductors of CYP are barbiturates and 
anticonvulsants (phenytoin and carbamazepine). They therefore decrease the oral 
bioavailability and plasma concentrations of CYP substrates such as warfarin, digoxin, 
amitriptyline, theophylline, and duloxetine (20). 
Enzyme inhibition: More common than induction (oxcarbazepine, carbamazepine, 
omeprazole, pioglitazone) is the inhibition of CYP enzymes (cimetidine, amiodarone, 
verapamil, escitalopram). The result is reduced metabolism of the substrate drugs (warfarin, 
digoxin, amitriptyline, theophylline), thus they may begin to accumulate within the body (20). 
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Enzyme inhibition, unlike the enzyme induction that may take weeks to progress, may occur 
in few days and cause rapid toxicity (20). 
 DRUG EXCRETION INTERACTIONS 
Changes in the urinary pH: The alkaline pH converts weakly acid drugs (pKa 3 to 7.5) to 
ionized molecules that are unable to reabsorb and therefore remain in the urine with which 
they get excreted from the body (20). The opposite is with the weak bases with pKa values 
from 7.5 to 10.5. This mechanism is considered also useful in cases of overdose, where the 
manipulation of urinary pH increases the removal of drugs such as methotrexate and 
salicylates (20). 
Changes in the renal blood flow: Production of renal vasodilatory prostaglandins partially 
controls the blood flow through the kidney. If the synthesis of these prostaglandins gets 
inhibited, as when using some NSADs (diclofenac, indometacin), the renal excretion of some 
drugs reduces and their effect enhances (lithium) (20).  
1.2.1.2. PHARMACODYNAMIC DRUG-DRUG INTERACTIONS 
Pharmacodynamic interactions occur between drugs with additive or opposing effects. 
 ADDITIVE INTERACTIONS 
Two drugs with the same pharmacological effect given concomitantly may have additive 
effects. Additive effects can occur with both the main effects of the drugs as well as their ADR 
(20). For example, two concomitantly prescribed CNS depressants (BZDs, antipsychotics, 
opioids) may have additive depressing effect and cause excessive sedation, falls, impaired 
cognitive functions and even respiratory depression. Potassium supplements and potassium-
sparing agents, such as ACEIs, combined together may provoke hyperkalemia, while 
simultaneous use of more drugs known to prolong QT interval (amiodarone, escitalopram) 
could result in torsade de pointes (TdP) (20). 
 ANTAGONISTIC INTERACTIONS 
Unlike the additive interactions, some pairs of drugs have activities opposite to one another 
(20). Coumarins are one such example, since they can prolong the blood clotting time by 
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competitively inhibiting the vitamin K`s effects. Other examples of antagonistic interactions 
are those between ACEIs and NSAIDs that have opposite antihypertensive effects, and 
antidiabetics and glucocorticoids whose combination may result in opposite blood glucose-
lowering effects (20). 
1.2.1.3. MOST COMMON DRUG-DRUG INTERACTIONS IN THE ELDERLY 
Some DDIs are intentionally provoked, since they improve the drug effects (drug synergism), 
some DDIs are not clinically significant, and some DDIs may easily lead to ADR. The risk of 
clinically significant DDIs increases with age and the number of used drugs (21). Most of 
them are often preventable. In the United States of America physicians and pharmacists 
identified 10 most dangerous DDIs in the elderly through the long term practice in the nursing 
homes. Those are summarized in the Table I (21). 
Table I: Examples of common drug-drug interactions in the elderly (21) 
DRUG 1 – DRUG 2 MECHANISM OF DDI CONSEQUENCES 
WARFARIN - NSAIDs ↓ platelet aggregation ↑ risk of hemorrhage 
WARFARIN - 
SULPHONAMIDES 
↓ metabolism of warfarin 
↓ warfarin binding to plasma 
proteins 
↑ risk of hemorrhage 
WARFARIN - 
MACROLIDES 
↓ metabolism of warfarin ↑ risk of hemorrhage 
WARFARIN – 
QUINOLONES 
↓vitamin K production 
altered metabolism of warfarin 
↑ risk of hemorrhage 
WARFARIN – PHENYTOIN altered metabolism of both drugs ↑effect of both agents 
ACEIs – POTASSIUM 
SUPPLEMENTS 
ACEIs inhibit the aldosterone 
production 
↑ risk of hyperkalemia 
ACEIs – 
SPIRONOLACTONE 
both drugs increase the serum 
potassium conc. 
↑ risk of hyperkalemia 
DIGOXIN – AMIODARONE ↓ clearance of digoxin ↑ risk of digoxin 
toxicity 
DIGOXIN – VERAPAMIL synergism in decreased heart 
contraction 
↑ risk of bradycardia 
THEOPHYLLINE - 
QUINOLONES 
↓ metabolism of theophylline ↑ risk of theophylline 
toxicity 
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Many researches indicate that the incidence of ADR is 2 to 3 times more likely in the elderly 
rather than in the younger population (21). According to a foreign study the incidence of ADR 
in patients from 70 to 103 years of age was 56 %, and from that up to 22 % was due to the 
clinically expressed DDIs (21). One German study examined DDIs in the elderly patients at 
the moment of their release from the hospital, and determined that 60 % of patients had at least 
one potential DDI and 12 % among them were potentially clinically harmful (21).  
1.2.1.4. LEXI-INTERACT ONLINE
TM
 
Consuming more prescribed medications at the same time, which is a common practice among 
the elderly patients, increases the risk of DDIs. However, not all the DDIs are prone to 
exacerbate actual clinical consequences. Using 5 concomitant drugs may increase the 
probability for potential DDIs by about 50 %, while having 7 or more medications prescribed 
at the same time grows the risk even to a 100 %. Clinically expressed DDIs are present in 20 
% of such patients (22). Drugs with low therapeutic index such as digoxin, carbamazepine, 
phenytoin, warfarin, are more likely to interact with other agents in clinically significant 
manner.  
Nowadays, several tools are available for identification and evaluation of DDIs in patients. 
One such example is Lexi-Interact Online™ (23). The database includes the detailed 
information on the interacting members, patient management, and risk-rating. According to 
this database, DDIs are divided in 5 risk-rating categories A, B, C, D and X which all serve as 
an indicator regarding how to respond to the interaction data (24):  
 A and B - No evidence of clinical concern and do not require any specific action. 
 C - The data demonstrates that specified agents have the potential to interact with each 
other in a clinically significant way, but the benefits of concomitant use usually 
outweigh the risks. However, the monitoring is advised. 
 D - Specific actions are required, such as regular monitoring, empiric dosage changes 
or choosing alternative agents in order to realize if the benefits of concomitant use of 
the agents are greater than its toxicity. 
 X - Concomitant use of agents that are forming this type of interaction are generally 
considered contraindicated.  
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1.2.2. POTENTIALLY INAPPROPRIATE MEDICATIONS IN THE ELDERLY 
Potentially inappropriate prescribing considers the use of medications whose risks for ADR 
outweigh the clinical benefits for the patient when there are more effective and lower‐risk 
alternative therapies available (25, 26). Also, according to some definitions inappropriate 
prescribing is considered as overprescribing and underprescribing. Age-associated 
multimorbidity and subsequent polypharmacy increase the prevalence of PIMs in the elderly 
and thereby the risk of ADR (25, 26). 
Thus, prescribing for the older adults is an each day growing public health concern, which is 
why several validated screening tools with explicit prescribing indicators are created. The 
intention of their creation is to prevent, evaluate and reduce the inappropriate prescribing in 
the elderly. In Europe, STOPP/START criteria and PRISCUS list are commonly used tools 
(26). These tools contain lists of medications with high potential for ADR in older adults and 
evidence-based recommendations for safer alternatives. Based on the PRISCUS list, the 
experts from seven European countries developed the EU(7)-PIM list, a screening tool that 
allows identification and comparison of PIM prescribing patterns for the elderly across the 
Europe (26). Even though Beers criteria were first published in the United States, nowadays 
many European studies use it to reassess the prevalence of PIM use among the elderly in 
Europe (26). 
An estimated overall prevalence of 22.6 % was reported after evaluation of potentially 
inappropriate prescribing in Europe. The percentage of elderly with at least one PIM in 
Slovenia in 2013 varied from 35.4 % (according to the PRISCUS list) to 60.2 % (according to 
the EU(7)-PIM list) (26). Regarding inappropriate prescribing in Croatia, a study conducted in 
2013 reported that 62.4 % of elderly patients received at least one PIM (27). The study was 
assessed using a comprehensive protocol based on a combination of Beers criteria and the 
French consensus panel which was published in 2012 by Suzana Mimica-Matanović and Vera 
Vlahović-Palčevski (27). 
1.2.2.1. BEERS CRITERIA 
The American Geriatrics Society (AGS) Beers Criteria is a list of PIMs to be generally 
avoided in the older adults, and in those with certain diseases (28). From 1991, when initially 
published, these criteria were one of the most commonly used sources for safer medications` 
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prescribing in the elderly. Since 1991 it has been updated multiple times, most recently in 
2015. The last update creation included a 13-member interdisciplinary expert panel with 
practice in geriatric medicine, pharmacy, nursing, and research (28). The framework 
development process included systematic literature review and evaluation of the evidence 
base. The quality of evidence and strength of recommendation for each criterion were rated 
independently by each panelist (28). In the latest update of Beers criteria, two new 
components have been added: drugs that require dose adjustment depending on kidney 
function, and the new table with potentially harmful drug–drug interactions. Other tables 
include lists of medications to be avoided in many or most older adults, medications to be 
avoided in older patients with specific diseases or syndromes, and medications to be used with 
great caution (28).  
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2. RESEARCH GOAL 
It is a well-known fact that in the elderly pharmacokinetics and pharmacodynamics of drugs 
can be changed. Physiological processes slow down with advancing age and so do the 
absorption, distribution, metabolism and excretion of the drug. This may cause an altered 
responsiveness to drug and increase the possibility of ADR. Alterations in the organism of an 
elderly patient can often be underestimated which can result in an inappropriate 
pharmacotherapy. Besides, elderly patients usually suffer from several diseases 
simultaneously and are using more drugs at the same time. Polypharmacy can increase the risk 
of ADR as well as potentially harmful DDIs in the elderly. 
The objective of our work was to determine the frequency of potential DDIs and PIMs among 
geriatric patients who were treated at the Department of Cardiology in Pula General Hospital. 
The retrospective study included the first 100 patients 65 years of age and above who were 
admitted to cardiology in the period from September 1
st
 2016 onwards and who had at least 2 
chronic systemic medications prescribed at the moment of their admission.  
We focused on DDIs of type D and X regarding the clinical significance, which were 
determined by Lexi-Interact Online
TM
. PIMs were determined using Beers criteria.  
This was the first such study ever conducted in Pula General Hospital. 
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3. METHODS 
Cardiology is one of the largest departments at Pula General Hospital and has most of the 
hospitalized patients, which is one of the reasons why it was selected for our research. We also 
assumed that there may be frequent admission of patients with numerous prescribed 
medications in their regular pharmacotherapy, since cardiovascular diseases and their 
consequences are the most frequent reason why people nowadays have to be medicated and 
hospitalized. 
Access to the data and the implementation of research were both approved by the ethics 
committee of Pula General Hospital (number of approval: 10605/16-1). 
3.1. SELECTION OF PATIENTS 
The retrospective analysis was comprised of 100 patients 65 years old and more who have 
been admitted at the Department of Cardiology in the Pula General Hospital since September 
the 1
st
 2016 onwards. Inclusion criteria included only those who, besides the corresponding 
age, had at least 2 chronic systemic prescription medications in the moment of their admission 
to the hospital. 
3.2. PATIENTS’ DATA COLLECTION 
The patients’ demographic data (age and sex), as well as the reason for admission to the 
hospital, co-morbidities and lists of chronic systemic prescription medications they had 
prescribed at the moment of hospitalization were obtained from the Hospital Information 
System (HIS) program. It is a medical information system for recording clinical data about 
patients. The purpose of the program is to automatize working processes in the hospital, which 
facilitates tracking and analyzing the condition of the patients since their admittance to their 
discharge from the hospital.  
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3.3. ANALYSIS OF THE COLLECTED DATA 
3.3.1. DEMOGRAPHIC AND MEDICAL DATA 
We have systemized the gathered data using Microsoft Excel 2010 and first we have processed 
them with descriptive statistics methodology. This approach led us to basic demographic and 
clinic conclusions about our group of patients. 
3.3.2. IDENTIFIED POTENTIAL DRUG-DRUG INTERACTIONS 
After extracting information about chronic systemic therapies for each patient from the HIS 
archive, we identified potential interactions between them using Lexicomp Online™ database 
(Wolters Kluwer, Inc., Hudson, OH, USA). It is a collection of the most trusted clinical 
information and clinical decision support tools. The clinical tool that we have used for 
detecting inappropriate drug-drug combinations was Lexi-Interact Online
TM
.
 
It is a drug and 
herbal interaction analysis program based on published scientific literature. It is designed to 
help its users to identify and avoid potentially inappropriate patient medication regimens.  
For this research we have focused only on the DDIs of types D and X, considering that they 
are clinically the most prominent ones. There were some drugs not recognized by Lexi-
Interact Online™, such as gliquidon, and therefore not included in the analysis. 
3.3.3. POTENTIALLY INAPPROPRIATE MEDICATIONS IN THE ELDERLY 
For identifying PIMs in the elderly, we used Beers criteria that were first published in 1991 by 
Dr Mark H. Beers. They were founded with the intention to reduce the incidence of the ADR 
in the elderly patients in the United States (28). These criteria have been used effectively 
across the world nowadays, so we have applied the latest version from 2015 to our research. In 
comparison with its previous version from 2012, the newest criteria have two additional tables 
with potentially harmful DDIs in the elderly and select drugs requiring renal dose adjustments 
(28). 
For analyzing chronic prescription medications of our patients, we took Beers Table 2 (28) 
into consideration. This table includes drugs and drug classes to avoid for many or most older 
adults. For each drug there is a rationale that helps us understand why the certain drug is 
considered potentially inappropriate in the elderly. It is followed by a recommendation, t.i. in 
16 
 
what circumstances the drug should be avoided, which is based on the certain quality of 
evidence (low, moderate, strong). For each recommendation there is also a “strength scale” 
(weak, strong, insufficient) that was decided by the Beers panel and based on the anticipated 
balance of risks and benefits from the medication (29). 
Besides Beers Table 2, we also included the Beers Table 3 (28) which is structured in the same 
way as the previous one, only that it enlists medications that are considered potentially 
inappropriate for the older adults who have certain diseases or disorders, since these may 
worsen their already existing health problems.  
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4. RESULTS AND DISCUSSION 
4.1. DEMOGRAPHIC AND MEDICAL DATA 
Considering that the subject of our retrospective study is focused on clinically significant 
DDIs and PIMs in the elderly, we included geriatric patients with at least 2 chronic systemic 
prescription medications who were admitted at the Department of Cardiology from September 
the 1
st
 2016 onwards.  
Average age of the patient was 78.2 ± 6.7 years (range 65 – 94 years) (Table II). From the 
total of 100 patients, 57 of them were women (57 %). The youngest female patient was 65 
years old, and the oldest one was 93 years old. The average age for women was 78.3 years. 
The youngest male patient was 65 years old, while the oldest was 94. The average age for men 
was slightly less, 78.0 years. 
Table II: Demographic and clinic data of included patients 
The number of patients: 100 
Men (%): 43 (43.0 %) 
Women (%): 57 (57.0 %) 
The average age of the patient ± SD: 78.2 ± 6.7 years old 
Minimum age: 65 years old 
Maximum age: 94 years old 
Total number of chronic diagnoses: 434 
The median and range of chronic diagnoses per patient: 4 (range 1-12) 
Total number of prescribed medications: 731 
The median and range of prescribed medications per patient: 7 (range 2-19) 
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The Figure 1 shows the distribution of patients according to their age and sex. The median age 
of our patient group was 78 years, and from 100 patients altogether, more than a half were 
female. The group that includes patients from 75 to 84 years of age resulted to be the most 
numerous (Figure 1). 
 
Figure 1: Distribution of patients according to their age and sex (m –male; f – female) 
According to the Croatian Bureau of Statistics (CBS), in 2016 Istria region was comprised 
48.6 % of male and 51.4 % of female population. People old 65 years and more took 20.6 % 
of the total number of Istrian population, which is 2.6 % more than in the year of 2011 (30). It 
is therefore statistically proven that there are more and more older adults each day. From the 
age of 45 years old onwards, the portion of women in Istria region gradually increases in 
comparison with men. Among the population old between 45 and 64 years old there was a 
predominance of women (51.2 %). In the older population groups going from 65 years of age 
to 84, there was even a bigger difference. Women took 56.4 % of the sample. At the age of 85 
and more, number of women in Istria region was almost three times higher than the number of 
men - 73.2 % (30). This kind of distribution of sexes was connected to the fact that women 
generally live seven years longer than the men. Thus it is not strange that considering our 
group of patients female sex was dominant. If we look upon the distribution of patients 
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considering their age and sex, we can see that in every age group there was a dominance of 
female patients. In the oldest group, which was consisted of the patients between 85 and 94 
years old, female population was double the size of male. From 18 patients in total, there were 
6 men and 12 women. That coincides with the fact that women live longer than men. 
Most common reasons for patients` hospitalization are enlisted in the Table III. Chest pain and 
dyspnea were most commonly encountered reasons for hospitalization. These two are usually 
associated with heart diseases, but can also be indicators of gastrointestinal (acid reflux, 
gallstones), lung-related (pneumonia, acute pulmonary embolism) or psychic (panic attack) 
complications. 
Table III: 5 most common reasons for hospitalization 
DIAGNOSE NUMBER OF PATIENTS 
(% CONSIDERING THE TOTAL NUMBER OF 
PATIENTS) 
CHEST PAIN 19  
(19.0 %) 
DYSPNEA 19 
(19.0 %) 
ACUTE HEART FAILURE 13 
(13.0 %) 
SYNCOPE 11 
(11.0 %) 
ATRIAL FIBRILLATION 10 
(10.0 %) 
 
4.1.1. CHRONIC DIAGNOSES 
We encountered a total of 434 chronic diagnoses from the medical documentation, which 
gives the median number of 4 chronic diagnoses per patient (range 1 – 12). The Table IV 
summarizes the median numbers of diagnoses considering the age and sex of the 100 patients. 
Surprisingly, it resulted that the patients from the oldest age group suffered from less chronic 
morbidities in comparison with the youngest patients. When considering the sex, there was no 
difference between women and men. Both sexes happen to have the same median number of 
chronic diagnoses in all the age groups.  
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Table IV: Number of diagnoses per patient (median) considering age and sex 
AGE GROUP 
 
(TOTAL NUMBER OF 
CHRONIC 
DIAGNOSES) 
ALL THE PATIENTS SEX 
FEMALE MALE 
M   E   D   I   A   N       A   N   D       R   A   N   G   E 
65 – 74 years 
(123) 
4 
(range 2 – 12) 
4 
(range 2 – 6) 
4 
(range 2 – 12) 
75 – 84 years 
(244) 
4 
(range 1 – 10) 
4 
(range 1 – 10) 
4 
(range 2 – 10) 
85 – 94 years 
(67) 
3 
(range 2 - 9) 
3 
(range 2 – 8) 
3 
(range 2 – 9) 
 
Next we have enlisted 5 most common chronic diagnoses among our patient group (Table V). 
Table V: 5 most common chronic diagnoses 
DIAGNOSE NUMBER OF PATIENTS 
(% OF DISEASE INCIDENCE CONSIDERING 
THE TOTAL NUMBER OF PATIENTS) 
ARTERIAL HYPERTENSION 67 
(67.0 %) 
DIABETES MELLITUS TYPE 2 46 
(46.0 %) 
ATRIAL FIBRILLATION 40 
(40.0 %) 
CARDIOPATHY 23 
(23.0 %) 
HYPOTHYROIDISM 19 
(19.0 %) 
 
According to the Istrian Institute of Public Health, in the year of 2016 the most of the older 
adults in Istria (59.2 %) suffered from the cardiovascular diseases (CVDs). The most common 
detected diagnoses among the elderly were hypertensive diseases (45.1 %), pulmonary heart 
diseases and other forms of heart diseases (20.3%), other and unspecified disorders of the 
circulatory system (13.3%), ischemic heart diseases (8.4%) and diseases of veins (6.3 %) (31). 
Regarding our results, most of the patients (67 %) suffered from AH, which was the most 
common among the hypertensive diseases in our patients. Also, DM 2 was present in almost a 
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half of the patients. Pulmonary heart diseases, such as pulmonary embolism and aneurysm 
were more common as reasons for hospitalization than as chronic diagnoses.  
According to Eurostat`s statistical report, cardiovascular diseases are the leading cause of 
death in the European Union (EU), and Croatia is among the states with the highest rate of  
deaths from the circulatory system diseases (32). 
 
4.1.2. CHRONIC SYSTEMIC PRESCRIPTION MEDICATIONS 
The local therapies are acting at the site of application and are often left out of interaction 
studies, which is why we took only chronic systemic prescription medications into 
consideration, since these are going through the first-pass metabolism and are therefore more 
probable to cause ADR and potential DDIs. The number of used chronic systemic prescription 
medications among our patient group was 731 in total, which resulted with the median of 7 
medications used per patient (range 2 – 19). The patient that used the most chronic systemic 
prescription medications used 19 medications at the same time (Table II). Table VI shows the 
median number of prescribed medications that were used in respective age groups. The highest 
median number of concomitantly used medications was in the patients who were between 65 
and 74 years old (Table VI). 
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Table VI: Number of prescribed medications per patient (median) considering age and sex 
AGE GROUP 
 
(TOTAL NUMBER OF 
PRESCRIBED 
CHRONIC SYSTEMIC 
MEDICATIONS) 
ALL THE PATIENTS SEX 
FEMALE MALE 
M   E   D   I   A   N       A   N   D       R   A   N   G   E 
65 – 74 years 
(250) 
8 
(range 2 – 19) 
8 
(range 2 – 15) 
9 
(3 – 19) 
75 – 84 years 
(365) 
6 
(range 2 – 15) 
6.5 
(range 2 – 15) 
5 
(range 3 – 15) 
85 – 94 years 
(116) 
6 
(range 2 -19) 
5 
(range 2 – 19) 
7 
(range 3 – 12) 
 
Unexpectedly, it resulted that the youngest patients (between 65 and 74 years) were using the 
most - 8 medications at the same time. When considering the sex from this age group of 
patients, men were having more concomitantly prescribed chronic systemic medications in 
comparison with women. In the other two, older, age groups the median number of prescribed 
chronic systemic medications per patient was the same, 6. In the age group consisted of 
patients from 75 to 84 years old females were having more prescribed medications than male 
patients, and in the oldest group it was vice versa. With this result our hypothesis that the 
number of prescribed chronic medications grows with aging was not confirmed. We assume 
that chronic medications in the oldest patients were prescribed with greater caution, since they 
are even more prone to be vulnerable to overdose and ADR of drugs, due to the advanced age-
related changes in their organism. Also, some medications such as statins, are often 
discontinued after the year of 75, since they may contribute to physical deconditioning and 
frailty (33). 
The group of patients who consumed 5 or less medications at the time was the largest (N=40; 
40 %). A little less patients (N=39; 39 %) was in the second group of patients who had 
prescribed from 6 to 10 chronic systemic medications at the same time. The next one was the 
group of 19 (19 %) patients who had from 11 up to 15 prescribed medications at the same time 
in their regular pharmacotherapy. There were only two patients (2 %) who consumed more 
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than 15 medications at the same time and both of them had prescribed 19 chronic systemic 
medications (Figure 2). 
 
Figure 2: Distribution of patients as per number of used medications 
60 % of patients were under high polypharmacy. Polypharmacy is defined as a simultaneous 
use of two or more medications per patient. High polypharmacy considers more than five 
concomitantly prescribed chronic medications (14). Two of our patients have been using 19 
chronic prescription medications at the same time, which was the maximum of concomitantly 
used chronic systemic prescription medications. Taking more medications concomitantly has 
been related to an increased risk of ADR, DDIs, PIMs, medication non-adherence, as well as 
with multiple geriatric syndromes and greater health care costs (18). 
Further on, during our insight into the chronic prescription medications of our patients we 
noticed that the most frequently prescribed medications among elderly were the ones to treat 
cardiovascular diseases. 346 from a total of 731 prescriptions were drugs from the Anatomical 
Therapeutic Chemical (ATC) classification group C (Cardiovascular system – 47.3 %). 
Second most prescribed medications were the ones from the group A (N=162; 22.4 %) with 
the affect on the alimentary tract and metabolism. Following them (N=96; 13.1 %) were the 
medications from the therapeutic group N with the affect on the nervous system (Figure 3). 
5 or less 6 to 10  11 to 15 More than 15 
N (patients) 40 39 19 2 
40% 39% 
19% 
2% 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
P
E
R
C
E
N
T
A
G
E
 O
F
 P
A
T
IE
N
T
S
 (
%
) 
NUMBER OF USED MEDICATIONS AT THE SAME TIME 
24 
 
 
Figure 3: Number of prescribed drugs according to the ATC classification 
Our results coincide with Agency for Medicinal Products and Medical Devices of Croatia 
(HALMED) statistics whose annual report of drug utilization for 2016 in Istria Region shows 
that the most prescribed medications were the ones to treat cardiovascular diseases from the 
ATC classification group C (34). Following them were the medications from groups A and N, 
as in our results. 
The next table presents the most frequently prescribed medications from each of the three 
most frequent ATC classification groups. C group was mostly comprised of the medications 
used for lowering high blood pressure and controlling chronic heart conditions. In the A 
group, frequently prescribed medications were the ones for regulating sugar and minerals in 
the blood. In the third most frequent ATC group, N, there were mostly anxiolytics, and 
hypnotics and sedatives. (Table VII). 
The list of all the enlisted chronic prescription medications is summarized in the Appendix A. 
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Table VII: The review of the most frequently prescribed medications from the three most 
frequent ATC classification groups 
ATC 
group 
DRUG NUMBER OF 
PRESCRIPTIONS 
DRUG PRESCRIPTIONS 
CONSIDERING THE 
TOTAL NUMBER OF 
PRESCRIBED 
MEDICATIONS (%) 
C 
 
 
Furosemide 62 8.5 
Bisoprolol 31 4.2 
Atorvastatin 29 4.0 
Carvedilol 16 2.2 
Trimetazidine 15 2.1 
A 
 
 
 
Pantoprazole 32 4.4 
Potassium chloride 29 4.0 
Metformin 15 2.1 
Insulin aspart 14 1.9 
Potassium citrate/potassium 
hydrogencarbonate/citric 
acid 
12 1.6 
N 
 
 
 
Diazepam 17 2.3 
Tramadol/paracetamol 10 1.4 
Alprazolam 7 1.0 
Oxazepam 4 0.6 
Zolpidem 4 0.6 
 
The most prescribed medication was furosemide, a loop diuretic from the therapeutic 
subgroup C03 of the ATC classification. 62 (62 %) out of 100 patients have been using it on a 
regular basis. From the ATC classification group A, mostly prescribed medication was PPI 
pantoprazole. There were also frequently prescribed antidiabetics and potassium supplements. 
Potassium has been often detected in chronic prescriptions of our patients, since it was often 
prescribed in a combination with diuretic furosemide, which is expected to increase the 
potassium and sodium excretion. Antidiabetic drugs, on the other hand, have often appeared 
because 46 (46 %) from the total of 100 patients suffered from DM 2. 
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When considering a total of 141 different chronic systemic enlisted medications, the most 
prescribed was again furosemide. Next most prescribed chronic systemic medications were 
PPI pantoprazole, and a β-blocker bisoprolol (Table VIII). 
Table VIII: 10 most frequently prescribed medications 
MOST FREQUENTLY 
PRESCRIBED MEDICATIONS 
 
 
ATC 
CLASSIFICATION 
GROUP 
 
NUMBER OF PRESCRIPTIONS 
(% of prescriptions considering the 
total number of prescribed 
medications) 
Furosemide C 62 (8.5 %) 
Pantoprazole A 32 (4.4 %) 
Bisoprolol C 31 (4.2 %) 
Atorvastatin C 29 (4.0 %) 
Potassium chloride A 29 (4.0 %) 
Acetylsalicylic acid B 26 (3.6 %) 
Warfarin B 25 (3.4 %) 
Diazepam N 17 (2.3 %) 
Carvedilol C 16 (2.2 %) 
Levothyroxine sodium H 16 (2.2 %) 
 
Furosemide is a loop diuretic, used for treating edema in congestive heart failure and chronic 
kidney disease. It is also occasionally prescribed as additional therapy for lowering the arterial 
pressure. It was almost in every patient prescribed in combination with potassium chloride or 
citrate because its action encourages increased excretion of sodium and potassium. According 
to an article from W.J. MacLennan , diuretics have been the most consumed medications in 
the elderly since the 1980’s (35). Even though they are valuable in many disorders which 
affect the older adults, they are also likely to cause ADR, such as electrolyte imbalance, 
dehydration and hypovolemia. Giving them in a combination with potassium supplements can 
reduce its possible toxicities. In that case checking serum electrolyte concentrations has to be 
done regularly, since some patients may develop hyperkalemia, which is in comparison with 
hypokalemia, more likely to result in cardiac arrhythmia and even death (35). Pantoprazole 
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was next most frequently encountered prescription medication in our patients. It is a PPI used 
for preventing or treating erosive damages caused by excessive acid production in stomach, 
due to a gastresophageal reflux disease (GERD), Zollinger-Ellison syndrome or Helicobacter 
pylori. The third most common medication in our patients was bisoprolol, a β-blocker used 
for treating hypertension, stable chronic angina or as additional therapy of stable chronic heart 
failure. According to the study (36), bisoprolol is considered more effective in comparison 
with other β-blockers, due to higher lipophility. Also, it is well tolerated and safe for use in the 
elderly (36). 
 
4.2. IDENTIFIED POTENTIAL DRUG-DRUG INTERACTIONS 
For detection of the potentially inappropriate combination of medications, we used the Lexi-
Interact Online™ database. During the clinical data collection we have encountered few 
prescriptions for gliquidon which was not included in this program`s database so we left it out 
of the interaction analysis. However, it was still included in the statistical processing of other 
clinical data. 
We focused only on the clinically most significant DDIs of types D and X. From the total of 
100 patients, in 49 of them, which is almost a half, we have detected at least one potential 
DDI. Therefore, the prevalence rate of potential DDIs among the patients was 49 %. From 49 
patients with potentially inadequate combination of medications, 22 (44.9 %) were male, and 
27 (55.1 %) were female.  
Even if prescription of more drugs per patient is a common and sometimes crucial practice, it 
was shown that the usual incidence of potential DDIs is close to 40 % in patients using 5 
drugs, and even more than 80 % in patients prescribed with 7 or more medications (37). 
Regarding our results, only 10 % (4/40) of patients, among those who were using 5 or less 
medications at the same time, had potential DDIs in their regular therapy. The incidence of 
DDIs was 61.5 % (24/39) in those who were taking from 6 to 10 medications, and almost a 
100 % (20/21) in those who had more than 10 prescribed chronic medications. 
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Figure 4: Median of drug-drug interactions as per number of used medications 
The hypothesis that the number of potential DDIs grows with the rising number of used 
medications was confirmed according to our results (Figure 4). Patients who were taking 5 or 
less medications had median number of DDIs 0. With more than 5 prescribed medications the 
potential for DDIs was growing bigger. There were only 2 patients who had more than 15 
medications prescribed and both of them were using 19 chronic medications at the same time. 
The consequence was a great number of potential DDIs, with the median number 15.5. This 
was almost 8x more than in the previous group of patients who were prescribed with 11 to 15 
medications. When considering all the 100 evaluated patients, the median number of potential 
DDIs per patient resulted to be 0 (range 0 – 24). Considering only the 49 patients with 
detected potential DDIs, the median number of potential DDIs per patient was 2 (range 1 – 
24). Most of the patients (22/49; 44.9 %) with identified potential DDIs among their chronic 
therapy had only one inappropriate combination of medications. The next one was a group of 
patients with two potential DDIs in their regular pharmacotherapy, while three and more 
potential DDIs were found rarely (Figure 5). 
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Figure 5: The distribution of potential drug-drug interactions per patient 
Taking into consideration the age of the included patients, we have established that most of the 
patients (23/49; 47 %) with detected DDIs in their regular pharmacotherapy were between 75 
– 84 years old, which did not came as an unexpectancy considering that this group of patients 
was the most numerous (Table IX).  
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Table IX: The distribution of patients with identified drug-drug interactions considering their 
age and sex 
 
AGE GROUP 
(TOTAL 
NUMBER OF 
PATIENTS) 
NUMBER OF PATIENTS WITH AT LEAST ONE 
IDENTIFIED POTENTIAL DDI 
 
MEDIAN OF 
POTENTIAL DDIs 
AND 
RANGE 
% OF PATIENTS 
WITH IDENTIFIED 
DDIs CONSIDERING 
THE TOTAL NUMBER 
OF PATIENTS 
FROM THE AGE 
GROUP 
 
% OF PATIENTS 
WITH IDENTIFIED 
DDIs CONSIDERING 
THE TOTAL 
NUMBER OF 
PATIENTS WITH 
DETECTED 
POTENTIAL DDIs 
(n=49) 
 
MEDIAN 
OF DDIs 
PER 
FEMALE 
PATIENT 
(range) 
MEDIAN 
OF DDIs 
PER 
MALE 
PATIENT 
(range) 
 
65 – 74 
(29) 
18 1 
(range 0 – 7) 
62.1 % 36.7 % 1 
(0 – 4) 
1.5 
(0 – 7) 
 
75 – 84 
(53) 
23 0 
(range 0 – 6) 
43.4 % 46.9 % 0 
(0 – 6) 
0 
(0 – 3) 
 
85 – 94 
(18) 
8 0 
(range 0 – 24) 
44.4 % 16.4 % 0 
(0 – 24) 
1 
(0 – 6) 
 
The median number of DDIs per patient was highest in the youngest age group – 1 (range 0 – 
7), which we have expected since the youngest ones were shown to use the most chronic 
prescription medications. Taking into consideration the sex of the patients with detected DDIs, 
it resulted that the median number of potential DDIs in the youngest and in the oldest group 
was higher in the male patients. Since the median number of prescribed medications per 
patient in the respective age groups was also higher in the men, this result was predictable. 
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Potential DDIs of only type D were detected in 38 (38 %) from the total of 100 patients. Drug 
combinations triggering DDIs of type X, on the other hand, appeared far less frequently. They 
were found only in 3 (3 %) patients. The combination of both categories of DDIs was present 
at 8 (8 %) patients (Figure 6). 
 
Figure 6: Number (percentage) of patients with and without detected potential drug-drug 
interactions 
All together we have detected 125 potential DDIs. There were 104 identified potential DDIs of 
type D (83.2 %). Potential DDIs of type X appeared a little less often so we have detected 21 
(16.8 %) of them in total. 
Considering the occurrence of potential DDIs based on the sex of the patients, the results have 
shown that the prevalence of both types of DDIs was greater in female patients (Table X). 
 
 
 
 
  
No potential 
DDIs; 51; 51% Only D type; 38; 
38% 
Only X type; 3; 
3% Both D and X 
types; 8; 8% 
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Table X: Incidence of drug-drug interactions based on the patients` sex 
 
SEX 
NO. OF IDENTIFIED 
POTENTIAL DDIs OF TYPE D 
(%) 
NO. OF IDENTIFIED 
POTENTIAL DDIs OF TYPE X 
(%) 
Women 66 (63.5 %) 12 (57.1 %) 
Men 38 (36.5 %) 9 (42.9 %) 
SUM 104 (100 %) 21 (100 %) 
 
75 (53.2 %) out of 141 different listed chronic prescription medications were involved in 
potential DDIs. 59 (41.8 %) of them triggered potential DDIs of only type D, while 6 out of 
141 (4.3 %) were identified in DDIs classifiable only as X. 10 of them (7.1 %) were involved 
in both D and X types of DDIs (Table XI). 
Table XI: Number of drugs identified in potential drug-drug interactions 
 NO. OF DRUGS PERCENTAGE 
No interactions 66 46.8 % 
D interactions only 59 41.8 % 
X interactions only 6 4.3 % 
Both D and X interactions 10 7.1 % 
SUM 141 100.0 
 
We have also systematized a table with enlisted medications from certain ATC classification 
groups to show which categories of drugs from our patients` chronic prescriptions are most 
likely to interact with other agents in clinically significant manner. The most of the drugs 
(N=21; 14.9 %) that were involved in detected potential DDIs classifiable as D were part of 
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the ATC classification group C, which was expected since the most frequently prescribed 
medications among our patients were the medications to treat cardiovascular diseases. 
Following them were the medications with the impact on the nervous system, from the 
therapeutic group N, and medications from the group A. Most of the drugs involved in 
interactions of type X were from the ATC classification groups N and R (Table XII). 
Table XII: ATC classification of all the medications that were identified in potential drug-drug 
interactions 
ATC CLASSIFICATION GROUPS NUMBER OF DRUGS 
INVOLVED IN 
POTENTIAL DDIs OF 
TYPE D 
NUMBER OF DRUGS 
INVOLVED IN 
POTENTIAL DDIs OF 
TYPE X 
A (Alimentary tract and metabolism) 14 3 
B (Blood and blood forming organs) 7 0 
C (Cardiovascular system) 21 1 
D (Dermatologicals) 0 0 
G (Genito-urinary system and sex hormones) 1 0 
H (Hormonal preparations, excluding sex 
hormones and insulin) 
1 0 
J (Antiinfectives for systemic use) 0 0 
L (Antineoplastic and immunomodulating 
agents) 
1 0 
M (Musculo-skeletal system) 3 0 
N (Nervous system) 18 6 
P (Antiparasitic products, insecticides and 
repellents) 
0 0 
R (Respiratory system) 2 5 
S (Sensory organs) 1 1 
V (Various) 0 0 
SUM  69 16 
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4.2.1. POTENTIAL DRUG-DRUG INTERACTIONS OF TYPE D ACCORDING TO 
LEXI-INTERACT ONLINE
TM
 
We summarized 10 drugs that were most frequently identified in potential DDIs classifiable as 
type D. Although the top of this list has been marked by 2 medications with the effect on 
blood clotting, most of these drugs were part of the ATC classification group N. N group 
represents medications with the effect on the nervous system (Table XIII). 
Table XIII: 10 drugs most frequently involved in potential drug-drug interactions of type D  
DRUG ATC 
CLASSIFICATION 
TOTAL NUMBER 
OF D 
INTERACTIONS 
NUMBER OF 
DIFFERENT D 
INTERACTIONS 
Warfarin B01AA03 12 6 
Clopidogrel B01AA04 12 5 
Allopurinol M04AA01 12 7 
Tramadol/paracetamol N02AX52 11 9 
Amiodarone C01BD01 9 6 
Diazepam N05BA01 7 5 
Pantoprazole A02BC02 7 1 
Phenobarbital N03AA02 7 7 
Tramadol N02AX02 6 6 
Vildagliptin A10BH02 5 4 
 
In the Table XIV we have enlisted 10 most frequently identified potential DDIs of type D 
according to Lexi-Interact Online
TM 
(38). 
The list of the other detected potential DDIs of type D is summarized in the Appendix B. 
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Table XIV: 10 most common drug-drug interactions of type D (38) 
DRUG 1 
 
DRUG 2 OR DRUG 2 
CLASS 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
CLOPIDOGREL PPIs 
(pantoprazole, rabeprazole) 
- (9) 
PPIs are strong 
inhibitors of CYP2C19 
inhibition of the 
methabolic activation 
of clopidogrel (PK). 
↓ serum concentrations 
of the active 
metabolite(s) of 
clopidogrel ↓ 
therapeutic effect of 
clopidogrel 
ALLOPURINOL ANTITHROMBOTIC 
AGENTS 
(warfarin, 
acenocoumarol) - (7) 
Allopurinol may inhibit 
the hepatic mtb of drug 
2 class (PK).
 
↑ anticoagulant effect of 
warfarin  
ACE - INHIBITORS 
(lisinopril, 
trandolapril, 
ramipril, 
ramipril/ 
hydrochlorothiazide, 
perindopril arginine/ 
amlodipine) - (5) 
Unknown. ↑ potential for allergic or 
hypersensitivity 
reactions to allopurinol 
(Stevens-Johnson 
syndrome (fatal), fever, 
arthralgia, and myalgia) 
TRAMADOL 
 
 
 
BZDs 
(diazepam, alprazolam, 
nitrazepam) - (4) 
Additive CNS 
depressing effects 
(PD). 
↑ depressing effect on  
CNS ↑ risk of 
exceeded sedation (falls 
and fractures), and 
slowed, difficult 
breathing 
ANTIPSYCHOTICS 
(promazine, 
quetiapine) - (4) 
AMIODARONE ANTITHROMBOTIC 
AGENTS 
(warfarin, 
acenocoumarol) - (4) 
Amiodarone may 
inhibit one or more 
enzymes responsible 
for drug 2 class mtb 
(PK). 
- ↑ anticoagulant effect 
of warfarin  
 
- the iodine content of 
amiodarone may cause 
hyperthyroidism  
alteration of the body's 
sensitivity to warfarin 
DIAZEPAM OPIOID ANALGESICS 
(tramadol (3), 
oxycodon (1)) 
Additive CNS 
depressing effects 
(PD). 
↑ risk of sedation and 
slowed or difficult 
breathing 
mtb=metabolism; PK=pharmacokinetics; PD=pharmacodynamics 
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Table XIV: 10 most common drug-drug interactions of type D (38) (cont.) 
DRUG 1 
 
DRUG 2 OR DRUG 2 
CLASS 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
SPIRONOLACTONE POTASSIUM 
CHLORIDE (3) 
Additive potassium 
increasing effect (PD). 
↑ hyperkalemic effect 
of potassium-sparing 
diuretics  ↑ incidence 
of hyperkalemia. 
VILDAGLIPTIN SULFONYLUREAS 
(gliclazide, 
glimepiride) - (3) 
Additive hypoglycemic 
effects (PD). 
↑ hypoglycemic effect 
of sulfonylureas  
hypoglycemia. 
ATORVASTATIN FENOFIBRATE (2) Fenofibrate may ↑ the 
plasma concentrations 
of HMG-CoA 
reductase inhibitors 
and/or their active 
metabolites (PK). 
↑ risk of 
musculoskeletal 
toxicity 
cont.=continued 
 
CLOPIDOGREL – PROTON-PUMP INHIBITORS 
According to the study from the 2010, the combination of clopidogrel with PPIs is not 
advisable because PPIs tend to be strong inhibitors of the enzyme CYP2C19 (39). Clopidogrel 
is a prodrug that has to be metabolized by this enzyme to the active metabolite, which means 
that concomitantly used clopidogrel and one of the PPIs may result in reduced anticoagulant 
effect. The study claims that patients who concomitantly received clopidogrel with one form 
of a PPI had a notably higher risk of rehospitalization due to MI or coronary stent placement, 
in comparison with the patients receiving clopidogrel alone (39). But more recent studies show 
that concomitantly administered PPIs, such as pantoprazole or rabeprazole, do not affect the 
pharmacokinetics and antiplatelet efficacy of clopidogrel in a clinically important way. 
Nevertheless, it is much safer to consider some other acid-lowering therapies, such as H2-
receptor antagonist famotidine, in patients taking clopidogrel due to the considerably lower 
inhibition potential for CYP (40). 
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ALLOPURINOL – ANTITHROMBOTIC AGENTS 
If you ask any pharmacist to name one drug that has a high risk of triggering dangerous drug 
interactions, many will instantaneously name warfarin. Hundreds of drugs can enlarge or 
reduce its effect due to the metabolism via CYP1A2, CYP2C9 and CYP3A4 (41). The drugs 
that inhibit these enzymes, such as allopurinol, may increase the plasma concentration of 
warfarin and consequently enhance the risk of hemorrhage. Instead of allopurinol, febuxostat 
may be taken into consideration for treating hyperuricemia, since this drug was not identified 
as potentially inappropriate in a combination with warfarin (42). 
ALLOPURINOL – ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS 
Allopurinol is also the xanthine oxidase inhibitor (XOI) which makes it a potential trigger for 
numerous interactions with other drugs. Often detected allopurinol`s interactions were those 
with ACEIs whose mechanism is still unknown, but impaired renal function may be a 
predisposing factor for increased potential of allergic reactions, such as Stevens-Johnson 
syndrome (38). Even though the clinic studies have been conducted only with captopril and 
enalapril, all of the ACEIs are considered inappropriate because of their similar chemical 
structures. When it comes to combining them with allopurinol it demands constant periodic 
monitoring of white blood cell counts, which may indicate potential development of 
inflammation reaction. Patients should be advised to immediately stop the use of drugs and 
seek medical help if they notice symptoms like chricopharyngeal spasm, dyspnea, swelling of 
the face or tongue, urticaria, rash, fever, arthralgia, or myalgia (43). Instead of ACEIs, patients 
could use other antihypertensive therapy with the impact on renin-angiotensin system (RAS), 
such as telmisartan that does not interact with allopurinol and is according to the study much 
safer alternative (44). 
TRAMADOL – PSYCHOLEPTICS 
BZDs, opioids and antipsychotics are all CNS depressants and highly addictive. Patients on a 
long-term use of BZDs quickly develop tolerance, which may result in reduced effect of 
opioids and antipsychotics (45). This may lead to patients` taking greater doses, which could 
result in profound sedation, and consequently, due to disrupted balance and impaired vision, 
falls and fractures (45). This is concerning since up to one-third of older adults with 
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specifically hip fracture die within a year. Also, the risk of hypotension may be increased with 
concomitant use of these agents, as well as dependency after long-term use. The major 
problem could be slowed breathing that often ends with coma, and even death (46). 
Considering that the elderly may have increased sensitivity to opioid analgesics, these should 
not be the first choice for reducing pain. For treating patients with mild pain nonopioid 
medications should be taken into consideration before all (47). Paracetamol given around-the-
clock may be an appropriate alternative for treating mild-to-moderate pain of musculoskeletal 
origin. Even though the study proposes reduction of paracetamol`s maximal daily dose from 4 
to 2 g (47), in the summary of product characteristics this suggestion is not demanded. If 
advancing to opioids for those with moderate to severe pain, it is essential to monitor for 
ADR. Patients should also be educated about the correct use of drugs with the aim to avoid 
potential development of sedation and consequent falls and fractures, and slowed breathing. 
AMIODARONE – ANTITHROMBOTIC AGENTS 
Amiodarone was often involved in potential DDIs with oral anticoagulants, where amiodarone 
was expected to increase their effect and consequently induce hemorrhage. Regarding the 
concomitant use of these, many studies have been conducted with the aim to determine the 
safety of this combination. Treatment of the AF includes both medications to control and 
maintain normal sinus rhythm, as well as to minimize the risk of thromboembolic events. At 
this point, no ideal antiarrhythmic or anticoagulant drug exists (48). Management of AF, 
especially in the elderly, should be based on the presence of comorbid diseases in every 
individual patient. Patients at risk for myocardial infarction (MI) must be given special 
attention and receive anticoagulation therapy, unless a true contraindication is present (48). 
According to guidelines issued by the American College of Chest Physicians (49), ASA 75 to 
100 mg or warfarin can both be used for MI prevention, depending on the presence of 
additional risk factors. ASA is considered safer than warfarin and can be used concomitantly 
with amiodarone. But if the patient is under a high risk of MI, warfarin may be needed. For 
maintaining the sinus rhythm, sotalol or dronedarone may be better alternatives in 
combination with warfarin. Anyhow, warfarin dosage may need to be modified and patient`s 
prothrombin time (PT) monitored regularly. Also, patients should be advised to seek 
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immediate medical help if they experience symptoms as blood in their urine or stools, 
vomiting, headache, dizziness, or weakness (50). 
DIAZEPAM – OPIOID ANALGESICS 
Combination of BZDs with other drugs that depress the CNS, such as opioid analgesics, may 
result in sedation and consequently lead to dangerous falls, fractures, and breathing 
depression. The need of such combination is sometimes unavoidable in the elderly, but in 
many cases also unnecessary. For reducing insomnia symptoms, prolonged-release melatonin 
could be better choice for older adults, combined with nonpharmacological approaches, such 
as Cognitive behavioral therapy which is, according to the Beck Institute (51), a structured 
type of psychotherapy focused on solving existing problems and teaching patients how to 
control dysfunctional thinking and behavior. 
SPIRONOLACTONE – POTASSIUM CHLORIDE 
Combining potassium-sparing diuretics and potassium salts should generally be avoided. 
Exceptions are cases with significant hypokalemia, or if serum potassium concentrations are to 
be monitored closely. If combined, patients should always be given dietary counseling and 
advised to seek medical attention if they experience muscular weakness, fatigue, arrhythmias, 
or bradycardia which could be the signs of hyperkalemia (38). 
VILDAGLIPTIN - SULFONYLUREAS 
Combination of sulfonylureas and dipeptidyl peptidase-4 (DPP-IV) inhibitors, in our case 
vildagliptin, increases hypoglycemic effect of DPP-IV inhibitors, and that is the situation 
which we try to avoid in the patients who suffer from DM 2. Sulfonylurea doses should be 
reduced and patients advised about the possible hypoglycemic events (38). 
ATORVASTATIN – FENOFIBRATE 
Unless the benefits of combining these drugs outweigh the potential risks, concurrent use of 
atorvastatin and fenofibrate should be avoided, considering the increased potential for 
developing myopathy and rhabdomyolysis (38). If the combination is prescribed, it is 
recommended to lower initial dosages of the atorvastatin. Patients should be warned to 
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promptly report any muscle pain, fever or dark-colored urine (52). The more secure choice in 
the older patients receiving fibrates would be fluvastatine, since it is the only statin that does 
not have a great potential for interactions with fibrates (38). 
 
4.2.2. POTENTIAL DRUG-DRUG INTERACTIONS OF TYPE X ACCORDING TO 
LEXI-INTERACT ONLINE
TM
 
Potassium took the first two places among drugs that were identified to have a great potential 
of forming DDIs of type X. Still, the most prone to interact with other drugs resulted to be the 
members of the ATC group A (Table XV). 
Table XV: Drugs involved in potential drug-drug interactions of type X 
DRUG ATC CLASSIFI- 
CATION 
A TOTAL 
NUMBER OF X 
INTERACTIONS 
NUMBER OF 
DIFFERENT X 
INTERACTIONS 
Potassium chloride A12BA01 9 6 
Potassium citrate A12BA30 4 4 
Ipratropium bromide A10AB05 4 3 
Tiotropium bromide R03BB04 3 1 
Aclidinium bromide/ 
formoterolum fumarate 
dihydrate 
R03AL05 3 3 
Escitalopram N06AB10 3 3 
Promazine N05AA03 3 3 
Quetiapine N05AH04 3 3 
Loratadine R06AX13 2 2 
Desloratadine R06AX27 2 2 
Dorzolamide/timolol S01ED51 1 1 
Amitriptyline N06AA09 1 1 
Bilastine R06AX29 1 1 
Amiodarone C01BD01 1 1 
Buprenorphine N07BC01 1 1 
Tramadol N02AX52 1 1 
 
Considering that there were much less drug combinations encountered in category X than in 
the category D, in the next tables we have enlisted all the detected potential DDIs of type X. 
The total sum of potential DDIs of type X was 21, which is 16.8 % of all of the identified 
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DDIs. Among the total of 21 interactions, there were 18 different potential DDIs of type X 
(Table XVI - XX). 
Table XVI: Potassium`s drug-drug interactions of type X (38) 
DRUG 1 or DRUG 1 
CLASS 
 
DRUG 2 
(Number of detected potential 
DDIs) 
MECHANISM OF 
DDIs 
POSSIBLE 
CONSEQUENCES 
POTASSIUM 
(chloride/citrate) -
solid oral dosage 
forms 
ANTICHOLINERGICS 
(tiotropium bromide, 
ipratropium bromide, aclidinium 
bromide) – (6) 
 
SYSTEMIC 
ANTIHISTAMINES 
(loratadine, desloratadine, 
bilsatine) – (4) 
 
ANTIPSYCHOTICS 
(quetiapine, promazine) – (2) 
 
ANTIDEPRESSANTS 
(amitriptyline) – (1) 
Anticholinergic 
effects of drug 2 = 
gastrointestinal 
motility ↓  
prolonged contact 
between potassium 
and the GIT 
mucosa (PK).
 
 risk of gastric and 
intestinal irritation 
and ulceration. 
PK = pharmacokinetics 
 
Solid oral dosage forms of potassium chloride or citrate may cause intestinal irritation and 
ulceration due to the prolonged contact between them and the GIT mucosa of an elderly 
patient, especially the one with the already existing GI diseases (53). In combination with 
anticholinergic drugs, this risk can additionally be increased because of the slowed motility of 
the GIT mucosa. Anticholinergics, antidepressants and antihistamines which we have enlisted 
from the archived prescriptions of our patients, were often combined with potassium, but 
luckily in the form of effervescent tablets. Although these are also solid dosage forms, they are 
considered safe since they need to be dissolved in water before the use (54). In Croatia, 
potassium as a chronic prescription drug is given only in the form of soluble powder, soluble 
tablets or effervescent tablets (55). 
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Table XVII: Anticholinergic`s drug-drug interactions of type X (38, 56) 
DRUG 1 or DRUG 1 
CLASS 
 
DRUG 2 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
ANTICHOLINERGICS 
(ipratropium bromide, 
tiotropium bromide, 
aclidinium bromide/ 
formoterol fumarate 
dihydrate) 
LORATADINE (1) Additive 
anticholinergic effects 
(PD). 
 risk for excessive 
anticholinergic effects 
(urinary retention, 
constipation, 
tachycardia, dry 
mouth...) 
ACLIDINIUM 
BROMIDE/ 
FORMOTEROL 
FUMARATE 
DIHYDRATE 
DORZOLAMIDE/ 
TIMOLOL (1) 
Opposing effects on β-
2 adrenergic receptors 
(PD) (56). 
Nonselective β-
blockers (timololum) 
may ↓ the 
bronchodilatory effects 
of β-2-agonists 
(formoterolum)  
bronchoconstriction 
 
!!!COPD AND 
ASTHMA PATIENTS 
ARE OF 
PARTICULAR 
CONCERN!!! 
PD=pharmacodynamics 
 
8 (8 %) patients from our study group suffered from chronic obstructive pulmonary disease 
(COPD). For reducing the symptoms they have regularly administered titropium bromide, 
ipratropium bromide and aclidinium bromide/formoterol fumarate dihydrate, which besides 
bronchodilatatory, have anticholinergic effects. Therefore, the combination of those with 
another anticholinergic drug, such as loratadine, should be given with great caution in such 
patients. Cetirizine, that did not show any specific DDIs in the studies, may be the right 
alternative for reducing allergy symptoms in the elderly (57).  
Dorzolamide/timolol is a local ophthalmic solution, which decreases the risk of potential 
DDIs, considering that its systemic absorption is lower in comparison with systemic 
preparations. However, for treating glaucoma in the elderly, prescribing another local carbonic 
anhydrase inhibitor such as brinzolamide that was shown to produce less ADR (local 
irritation), would be a safer alternative (58). 
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Table XVIII: Antipsychotic`s drug-drug interactions of type X (38) 
DRUG 1 or DRUG 1 
CLASS 
 
DRUG 2 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
ANTIPSYCHOTICS 
(quetiapine, 
promazine) 
ESCITALOPRAM (2) 
 
ANTIPSYCHOTICS 
(interactions between 
them) – (2) 
Quetiapine and promazine 
have similar structure as 
other agents known to 
prolong the QTc interval 
 additive QTc-
prolonging effects (PD). 
 risk of ventricular 
arrhythmias, including 
TdP. 
 
 
Concomitant use of more QTc-prolonging agents should be avoided, unless the benefits of 
parallel consumption outweigh the potential risk for ADR due to the DDIs. If combined, 
caution and monitoring are recommended, particularly in the elderly (59). Patients should also 
be warned to ask for quick medical attention if they experience dizziness, irregular heart 
rhythm, shortness of breath, or syncope since these could be an indication for the occurrence 
of TdP (59). 
Table XIX: Amiodarone`s drug-drug interactions of type X (38) 
DRUG 1 or DRUG 1 
CLASS 
 
DRUG 2 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
AMIODARONE ESCITALOPRAM (1) Additive arrhythmogenic 
effects (PD). 
 risk of ventricular 
arrhythmias, including 
TdP. 
 
Concomitant use of class Ia (quinidine, procainamide, disopyramide, ajmaline) or class III 
antiarrhythmic agents (amiodarone, dofetilide, ibutilide, dronedarone) with other drugs that 
are expected to prolong the QT interval should be avoided unless the benefits are probable to 
outweigh the risks (38). Clinical monitoring is recommended to be regularly applied if 
concurrent use is necessary. Patients should be advised to seek medical help if they experience 
symptoms like dizziness, irregular heart rhythm, shortness of breath, or syncope since all of 
these could be indicators for the occurrence of TdP (60). 
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Table XX: Opioid`s drug-drug interactions of type X (38) 
DRUG 1 or DRUG 1 
CLASS 
 
DRUG 2 
(Number of detected 
potential DDIs) 
MECHANISM OF 
DDI 
POSSIBLE 
CONSEQUENCES 
TRAMADOL BUPRENORPHINE 
(transdermal patch) - (1) 
Competition/ 
antagonism at μ-opioid 
receptors (PD). 
- ↓ analgesic effect of 
tramadol.  
-↑ risk for withdrawal 
symptoms 
 
!!!THESE EFFECTS 
APPEAR TO INCREASE 
WITH HIGHER 
BUPRENORPHINE DOSES, 
GREATER OPIOID 
DEPENDENCE, AND 
SHORTER TIME BETWEEN 
OPIOID AGONIST DOSE 
AND BUPRENORPHINE 
DOSE!!! 
 
Recent studies have shown that buprenorphine transdermal patch is a suitable choice for the 
treatment of chronic pain in the elderly (61). First of all, buprenorphine appears to be safer in 
comparison with other potent opioids such as fentanyl and morphin, since the risk of 
development toxicities was demonstrated to be lower. Also, the transdermal patch, besides 
being easily applied which is very important in elderly population, allows its matrix for slow 
release of active substance and damage does not produce dose dumping (61).  
However, concomitant use of buprenorphine and tramadol is generally not recommended, 
especially not in the elderly (38). Several recent studies claim that buprenorphine may 
antagonize tramadol`s effects and thereby require greater opioid agonist doses, which may 
result in withdrawal symptoms (38). These effects seem to increase with higher buprenorphine 
doses, greater opioid dependence, and shorter period of time between tramadol dose and 
buprenorphine dose. If patients receive this combination, it is advised to to increase the 
tramadol`s dose, along with necessary monitoring for symptoms of high dose requirements or 
withdrawal in opioid-dependent patients (38). 
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4.3. POTENTIALLY INAPPROPRIATE MEDICATIONS IN THE 
ELDERLY 
Among the 100 patients evaluated 61 (61 %) were on at least 1 PIM at admission to hospital, 
according to Beers criteria. Female patients accounted 65.6 % (N=40) of the sample. Most of 
the patients among those with identified PIMs (N=35; 57.4 %) had only one prescription 
medication considered potentially inappropriate. With the growing number of PIMs, the 
number of patients was falling. 4 PIMs per patient, which was the maximum in our research, 
were identified in only one patient of female sex (Figure 7). 
Figure 7: Distribution of patients according to the number of identified potentially 
inappropriate medications and sex of the patients 
We encountered a total of 98 potentially inappropriate prescription medications with the 
median number of 1 PIM per patient (range 0 – 4). A total of 731 chronic medications were 
prescribed among the 100 patients with the median number 7 per patient (range 2 – 19). 
Overall, 13.4 % (N=98) of all chronic medication prescribed were detected as inappropriate 
according to Beers criteria. 
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To verify the assumption that the number of PIMs in the elderly grows with the increasing 
number of prescribed medications, we created the Figure 8. The results were positive, since 
the patients who were having the most prescribed medications resulted to have the highest 
median number of PIMs (Figure 8).  
 
Figure 8: Median of potentially inappropriate medications as per number of used 
medications 
According to the distribution of PIMs based on the age of patients, from the total of 29 
patients between 65 and 74 years old, 20 of them (69 %) had at least one PIM in their regular 
therapy. In the oldest age group, only 9 out of 18 patients in total (50 %) were prescribed with 
at least one PIM. (Table XXI).  
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Table XXI: The distribution of patients with identified potentially inappropriate medications 
considering their age and sex 
 
AGE GROUP 
(TOTAL 
NUMBER OF 
PATIENTS) 
NUMBER OF PATIENTS WITH AT LEAST ONE 
IDENTIFIED PIM 
 
MEDIAN 
OF PIMs 
AND 
RANGE % OF PATIENTS WITH 
IDENTIFIED PIMs 
CONSIDERING THE 
TOTAL NUMBER OF 
PATIENTS 
FROM THE AGE 
GROUP 
% OF PATIENTS 
WITH IDENTIFIED 
PIMs CONSIDERING 
THE TOTAL 
NUMBER OF 
PATIENTS WITH 
DETECTED PIMs 
(n=61) 
MEDIAN 
OF PIMs 
PER 
FEMALE 
PATIENT  
(range) 
MEDIAN 
OF PIMs 
PER 
MALE 
PATIENT 
(range) 
 
65 – 74 
(29) 
 
20 
 
 
1 
(range 0 - 3) 
69.0 % 
 
32.8 % 
 
1 
(0 – 3) 
0.5 
(0 – 3) 
 
75 – 84 
(53) 
 
32 
 
 
1 
(range 0 – 4) 
60.4 % 
 
52.4 % 
 
1 
(0 – 4) 
0 
(0 – 3) 
 
85 – 94 
(18) 
 
9 
 
0.5 
(range 0 – 3) 
50.0 % 
 
14.8 % 
 
0 
(0 – 2) 
1 
(0 – 3) 
 
Considering the sex of the patients, the median number of PIMs per patient was higher in 
female patients, except for the oldest age group where men were having more PIMs 
prescribed. 
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4.3.1. POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS 
BASED ON PHYSIOLOGICAL CHANGES 
From 141 different enlisted chronic medications, 15 (10.6 %) of them were identified as PIMs, 
according to Beers Table 2, which assorts PIMs based on physiological changes that are 
considered to be present in the elderly. When considering the total of 98 detected PIMs, 96 
(97.9 %) of them were from this table. 
Based on these criteria, most of the inappropriate medications in our patients belonged to the 
ATC classification group A, and these were often prescribed PPIs (N=41; 41.8 %). Following 
them were the prescription medications from the ATC classification group N - anxiolytics, 
antidepressants, sedatives and antiepileptics (N=37; 37.8 %). Next were the antihypertensives 
and antiarrhythmics from the therapeutic group C (N=16; 16.3 %). The last place was shared 
both between the group L with megestrol (N=1; 1 %) that was used as a substitute hormonal 
therapy, and the group M with NSAID ibuprofen (N=1; 1 %) (Table XXII). 
Besides being frequently identified in potential DDIs, PPI pantoprazole was also the most 
common PIM (32/96; 33.3 %) according to the Beers criteria. Next one was diazepam (17/96; 
17.7 %), BZD derivative which has an anxiolytic and hypnotic effect. Following them was the 
antiarrhythmic amiodarone (14/96; 14.6 %). Last two, among the five most frequent PIMs, 
were another anxiolytic alprazolam, and one more PPI rabeprazole. 
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Table XXII: ATC classification of identified potentially inappropriate medications according 
to Beers Table 2 
ATC 
GROUP 
ATC 
SUBGROUP 
POSSIBLE CONSEQUENCES 
ACCORDING TO BEERS 
CRITERIA 
DRUGS 
IDENTIFIED IN 
OUR RESEARCH 
NO.  
OF 
PRESCRIPT
IONS 
A Drugs for peptic 
ulcer and GORD 
Risk of infection with Clostridum 
difficile infection and bone loss and 
fractures 
PANTOPRAZOLE 
RABEPRAZOLE 
ESOMEPRAZOLE 
32 
6 
3 
N Anxiolytics May increase the  risk of cognitive 
impairment, delirium, falls, and 
fractures in the elderly 
DIAZEPAM 
ALPRAZOLAM 
OXAZEPAM 
LORAZEPAM 
17 
7 
4 
1 
Hypnotics and 
sedatives 
Risk of delirium, falls and fractures 
in older adults 
ZOLPIDEM 4 
Antidepressants Highly anticholinergic, sedating, 
and cause orthostatic hypotension. 
PAROXETINE 
AMITRIPTYLINE 
2 
1 
Antiepileptics High rate of physical dependence; 
greater risk of overdose at low 
dosages 
PHENOBARBITAL 1 
C Antiadrenergic 
agents, 
peripherally 
acting 
High risk of orthostatic 
hypotension 
DOXAZOSIN 2 
Antiarrhytmics Amiodarone may have greater 
toxicities than other 
antiarrhythmics used in AF 
AMIODARONE 14 
L Hormones 
(Progestogens) 
Increases the risk of thrombotic 
events and possibly death in older 
adults 
MEGESTROL 1 
M NSAID Increased risk of GIT bleeding or 
peptic ulcer 
IBUPROFEN 1 
TOTAL 15 96 
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4.3.1.1. PROTON-PUMP INHIBITORS 
Quality of evidence: High 
Strength of recommendation: Strong 
 
 PANTOPRAZOLE (32) 
 RABEPRAZOLE (6) 
 ESOMEPRAZOLE (3) 
PPIs are considered inappropriate for chronic use in the elderly, since they can increase the 
risk of infection with Clostridum difficile and cause bone loss and fractures (62). Scheduled 
use for more than 8 weeks should be avoided unless the patients are using high-risk 
medications such as oral corticosteroids or NSAIDs for chronic use, or are experiencing some 
difficulties due to erosive esophagitis, Barret`s syndrome and pathological hypersecretion 
(62). 
There was a high prevalence of PPIs chronic prescriptions among the 100 patients evaluated. 
41 (41 %) of them have been taking it on a regular basis. However, only 2 patients from the 
total of 41 with identified PPI prescriptions have been diagnosed with chronic gastritis, and 1 
female patient was on dexketoprofen to ease the cancer pain. For all the other patients the 
therapeutic indications for use of PPIs were not clear. There were 3 (7.3 %) patients who had 
no chronic conditions related to GIT, no prescribed NSAIDs, no polypharmacy, but were 
regularly using PPIs. 
Also, one patient who has been diagnosed with chronic gastritis and was using concomitantly 
more than 5 medications, did not have prescribed any gastro-protective medication. One 
patient has been taking ibuprofen 600 mg for the long-term at the same time as many other 
drugs, but also did not have a prescription for any PPI. 
To make sure that PPIs benefits outweigh the risk of the treatment, older adults should be 
periodically evaluated for the need for long-term use of PPI, or step-down to a H2-receptor 
antagonist, such as famotidine which is considered safe in older adults (40). 
4.3.1.2. BENZODIAZEPINES 
Quality of evidence: Moderate 
Strength of recommendation: Strong 
 
a) Short- and intermediate- acting BZDs 
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 ALPRAZOLAM (7) 
 OXAZEPAM (4) 
 LORAZEPAM (1) 
 
b) Long-acting BZDs 
 DIAZEPAM (17) 
All BZDs enhance the risk of cognitive impairments, delirium, falls and fractures. It is 
recommended to avoid them in older adults, since they have enhanced sensitivity to its effects, 
especially the long-acting ones (28). Even though long-acting BZDs may be appropriate for 
seizure and severe anxiety disorders, caution is needed with prescribing it, considering that the 
metabolism of long-acting agents in the elderly is decreased and sensitivity to its effects is 
higher (28). Most of the recommendations about the use of BZDs are based on the “moderate” 
evidence quality and are given with a “strong” recommendation, except in older patients with 
a history of falls and in those who are already taking 2 or more drugs with the impact on the 
CNS where the recommendation is based on “high” quality of evidence (28, 47). In 4 (4 %) of 
our female patients, who were diagnosed with the breast cancer, Parkinson`s disease and 
epilepsy, was detected simultaneous chronic use of BZDs with 2 or more other CNS agents. 
In the USA, insomnia and anxiety are the most frequent reasons why elderly are prescribed 
with BZDs (63). Most studies on BZDs effects in these 2 indications were conducted in 
patients younger than 65 years of age, which is why evaluating long-term efficacy is lacking. 
This is often incorrectly interpreted as evidence that BZDs are having positive effects (64). 
None among our patients who were using BZDs regularly have been diagnosed with insomnia. 
Among the 29 patients with BZD prescriptions, only 2 (6.9 %) of them suffered from 
depression, and one (3.4 %) was diagnosed with anxiety disorder. 6 (20.7 %) of them have 
been diagnosed with chronic diseases that may be connected to the use of the anxiolitycs. 
Those were the patients with trigeminal neuralgia, cervical syndrome, Parkinson`s disease, and 
breast cancer. The rest of the patients were having BZD concomitantly prescribed with 
medications to treat AH or heart conditions. The purpose of their frequent use in these patients 
may be to calm the patients with the higher risk of further cardiovascular complications.  
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To reduce the unjustified abuse of BZDs and negative consequences that they may cause, 
physicians should educate their older patients about the potential risk of developing 
dependence when on long-term therapy with BZDs. Before the cessation of BZDs patients 
should be offered with tapering protocols (46) that consist of scheduled gradual dose reduction 
with the aim to make potential withdrawal process more bearable. Giving patients written 
tapering plan was shown to be among the most helpful strategies in discontinuing BZDs (46). 
Alternatives: 
a) INSOMNIA 
The antidepressants doxepin and mirtazapine may be good alternatives for treating insomnia 
in the elderly. Doxepin is a Food and Drug Administration-approved medication for insomnia, 
and the Beers criteria permit its use at dosages lower than 6 mg/d in the older adults. Even at 
such low doses, doxepin is expected to be highly selective for H1-receptors and to induce 
sleep effectively, without expressing anticholinergic effects (65). 
Also, prolonged-release melatonin given as a first-line prescription with 13 weeks' posology 
was shown to be a good alternative for sleep quality improvement in the elderly (66). 
Even though there is a lack of clinical studies to evaluate the effectiveness and safety of herbs, 
some of them such as valerian (Valeriana officinalis), hops (Humulus lupulus) and passion flower 
(Passiflora incarnata L), are considered potentially effective in treating insomnia (67, 68, 69). 
b) ANXIETY 
Nonpharmacological approaches, such as Cognitive Behavioral Therapy that considers sleep 
hygiene education, cognitive therapy, and behavioral interventions, were shown to reduce 
worry and depression, as well as to improve the mental health of older patients diagnosed with 
generalized anxiety disorder (70, 71). 
Duloxetine, a serotonin-norepinephrine reuptake inhibitor, can be used for treating anxiety in 
the elderly, except if the creatinine clearance is lower than 30 mL/min (71). 
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Selective serotonin reuptake inhibitors (SSRIs) - sertraline, escitalopram and citalopram 
can be used in older adults, but with required caution (71). Sodium levels should be regularly 
monitored since SSRIs may cause hyponatremia or the inappropriate antidiuretic hormone 
secretion syndrome. The exception is paroxetine, SSRI with strong anticholinergic effects that 
due to a higher risk for falls and fractures needs to be avoided in the elderly (71). 
4.3.1.3. HYPNOTICS (other than BZD) 
              Quality of evidence: Moderate 
              Strength of recommendation: Strong 
 ZOLPIDEM (4) 
 
BZD-receptor agonists should be avoided since they may cause ADR similar to those of BZDs 
in the elderly (delirium, falls and fractures). Also, they resulted to give minimal improvement 
in sleep latency and duration (28).  
From the 4 (4 %) patients in whom we detected the use of zolpidem, none of them was 
diagnosed with the chronic sleeping disorders, but with co-morbidities such as DM 2 and 
cardiovascular irregularities. 
4.3.1.4. ANTIDEPRESSANTS 
Quality of evidence: High 
Strength of recommendation: Strong 
 
 PAROXETINE (2) 
 AMITRIPTYLINE (1) 
 
It is recommended to avoid antidepressants with the highly anticholinergic and sedating 
effects in the elderly, since these have a higher potential for falls and fractures. Also, the 
orthostatic hypotension may be caused. Better alternatives in the elderly would be other SSRIs 
with less expressed anticholinergic effects, such as sertraline and escitalopram (71). 
We did not encounter any records about depressive disorders in patients taking paroxetine. 
Regarding the amitriptyline, we detected its use in only one patient who was diagnosed with 
chronic depression. 
 
54 
 
4.3.1.5. BARBITURATES 
Quality of evidence: High 
Strength of recommendation: Strong 
 
 PHENOBARBITAL (1) 
 
Clinical studies (72) suggest that phenobarbital is potentially inappropriate for older adults, 
because they are more prone to the adverse cognitive effects of this drug due to the changed 
pharmacokinetics and pharmacodynamics. This could increase patients’ risk of falls and 
fractures. A long-term use may also develop dependence, which is why phenobarbital`s use 
has to be discontinued gradually (72).  
Even though phenobarbital is a powerful antiepileptic, it has significant cognitive effects and 
according to certain studies, has also the possibility of inducing osteoporosis. Besides that, it is 
often involved in interactions with other drugs due to its hepatic metabolism (73). One of our 
patients had a prescription for the chronic use of phenobarbital due to the epilepsy. We cannot 
say if it was the right choice, since all the antiepileptics have certain disadvantages, especially 
in the elderly. Antiepileptic drug selection usually depends on the physician’s individual 
assessment of patient`s overall medical condition. The most important is to monitor the 
patient for potential ADR and to successfully control the seizures. 
4.3.1.6. PERIPHERAL ALPHA-1 BLOCKERS 
 Quality of evidence: Moderate 
 Strength of recommendation: Strong 
 
 DOXAZOSIN (2) 
 
According to the Beers criteria, use of doxazosin as a routine treatment for hypertension 
should be avoided considering the potential risk of orthostatic hypotension. Among the total of 
100 patients, 2 (2 %) of them were taking doxazosin as a combined therapy for AH. We found 
no information about them experiencing possible episodes of orthostatic hypotension. 
Even though doxazosin is considered inappropriate in the elderly according to these criteria, 
some studies have shown that this α-1-adrenoceptor antagonist has positive effects on high 
blood pressure, and also on lipid profiles and glycemic index (74). This makes it an attractive 
choice of therapy for elderly patients, especially those who have co-morbid disorders such as 
DM 2 or dyslipidemia. In addition, doxazosin is administered once daily, either in the morning 
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or the evening, which may contribute to compliance, an important consideration in the older 
adults (74). 
4.3.1.7. ANTIARRHYTHMICS 
Quality of evidence: High 
Strength of recommendation: Strong 
 AMIODARONE (14) 
Even though amiodarone is considered very effective for maintaining sinus rhythm, it is 
expected to have greater toxicities than other antiarrhytmics used in AF, such as Na-channel 
blocking agent propafenone, and β-blockers sotalol and metoprolol. Thus it should be 
avoided as a first-line therapy for AF, unless the patient suffers from heart failure or 
substantial left ventricular hypertrophy (28). 
14 (14 %) of our patients have been prescribed with amiodarone. Just in one of them we did 
not manage to detect indication for its use. This patient was diagnosed with DM 2 and AH, 
and was regularly taking glimepiride, ramipril and amiodarone. In the other 13 patients we 
have encountered chronic diagnoses, such as AF, cardiomyopathy, chronic heart failure, 
angina pectoris and aortic stenosis. 
4.3.1.8. ESTROGENS WITH OR WITHOUT PROGESTINS 
               Quality of evidence: Moderate 
               Strength of recommendation: Strong 
 
 MEGESTROL (1) 
Megestrol is recommended to be avoided since it enhances the risk of thrombotic events which 
could even result with death in older adults. According to American Cancer Society (75) 
megestrol use was more often in the past. Due to the high risk of ADR, aromatase inhibitors 
(letrozole, anastrozole, exemestane) and estrogen receptor antagonists (tamoxifen, 
toremifen, fluvestrant) are nowadays considered safer for treating breast cancer in the older 
adults (75). Megestrol was used by one (1 %) female patient that has been diagnosed with 
breast cancer. In such patients it is important to weigh up the benefits and risks of treatment. 
4.3.1.9. NSAIDs, oral 
              Quality of evidence: Moderate 
              Strength of recommendation: Strong 
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 IBUPROFEN (1) 
 
Ibuprofen`s chronic use is considered inappropriate in older adults, especially those with 
existing GIT problems or in those concomitantly prescribed with oral corticosteroids, 
anticoagulants and antiplatelet agents. NSAIDs increase the risk of GIT bleeding or peptic 
ulcers. Preferred analgesics in older adults that may have a lower risk of ADR include 
paracetamol in mild-to-moderate pain, or low-dose opioid agents (tramadol) in combination 
with paracetamol in moderate-to-severe pain (76). If NSAIDs are required, PPIs or 
misoprostol are recommended to be taken in combination with it (28). 
We detected the use of ibuprofen in only one (1 %) patient, but the reason for its use was not 
clear. We also noticed that the patient did not use any gastro-protective medication at the same 
time, but was using warfarin. He was admitted to the hospital because of the newly established 
pulmonary edema. 
 
4.3.2. POTENTIALLY INAPPROPRIATE MEDICATION USE IN OLDER ADULTS 
DUE TO DRUG–DISEASE OR DRUG–SYNDROME INTERACTIONS 
Among the 100 patients evaluated, there were only 2 (2 %) patients that had prescription 
medications considered inappropriate according to Beers Table 3, which enlists PIMs in the 
elderly based on the chronic diagnosis the older adults suffer from. According to this table, we 
have found only two (2.1 %) inappropriate medications from the total of 98 detected PIMs and 
2 (1.4 %) from the total of 141 diverse prescribed medications. They were identified in 2 
female patients (Table XXIII). 
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Table XXIII: ATC classification of identified potentially inappropriate medications according 
to Beers Table 3 
ATC group ATC subgroup CHRONIC DISEASE - 
CONTRAINDICATED DRUG 
No. OF 
PRESCRIPTIONS 
C Selective calcium 
channel blockers with 
direct cardiac effect 
cardiomyopathy verapamil 1 
N Opioids epilepsy tramadol 1 
 
4.3.2.1. HEART FAILURE – NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS  
Quality of evidence: Moderate 
Strength of recommendation: Strong 
 
Verapamil was detected in one of our female patients that suffered from cardiomyopathies. 
According to Beers criteria, calcium channel blockers have the potential to encourage fluid 
retention and exacerbate heart problems in older patients with heart failure. β-blockers may be 
an appropriate alternative (77). 
 
4.3.2.2. EPILEPSY – TRAMADOL 
Quality of evidence: Low 
Strength of recommendation: Strong 
 
Even though the quality of evidence for this recommendation is low, the caution is needed 
with prescribing CNS-acting agents, such as tramadol, in patients with epilepsy or chronic 
seizures. One of our female patients was detected to use tramadol while suffering from 
epilepsy. According to Beers criteria, tramadol may lower seizure threshold. Anyhow, it may 
be acceptable if the seizures are well-controlled or if some other alternatives are not effective. 
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4.4 COMPARISON OF THE RESULTS WITH OTHER STUDIES 
In the end we have summarized the table with the number of patients without any DDI and 
PIM (Table XXIV). More than a half, precisely 51 (51 %) of them, had no potential DDIs, and 
in 39 (39 %) of them we did not detect any PIM. Among the 100 geriatric patients included in 
the study, only 30 (30 %) of them had no potential DDIs among their systemic chronic therapy 
and no PIMs. 
Table XXIV: The number of patients without potentially harmful prescriptions 
The no. of patients without identified potential DDIs: 51 
The no. of patients without detected PIMs: 39 
The no.of patients without both DDIs and PIMs: 30 
 
Comparing the results of our study to other similar ones, we concluded that there was a high 
prevalence of both DDIs and PIMs among our patients` group. In 2013 a 
pharmacoepidemiological study was conducted in Slovenia, where the prevalence of PIMs in 
the elderly has been reassessed (26). The study included Slovenian geriatric population aged 
65 or more years that had at least one prescribed medication in 2013. For detection of PIMs 
EU(7)-PIM list, Beers criteria, PRISCUS list and Austrian criteria have been considered. 
Evaluated was only the potentially inappropriate prescribing and not actually harmful. 
Proportion of elderly with at least one PIM varied from 35.4 % (according to the PRISCUS 
list) to 60.2 % (according to the EU(7)-PIM list). Regarding Beers criteria, 55.8 % of patients 
were exposed to at least one PIM, which is a little bit lower than in our study, where it is 61 % 
(26).   
In Croatia two big studies were conducted regarding PIMs in the elderly. In 2011 a 
prospective study evaluated the pharmacotherapy of geriatric patients who were hospitalized 
at Clinical Hospital Center Osijek. The aim was to evaluate PIMs as well as their correlation 
to the reasons of hospitalization. PIMs were identified according to Beers criteria. 42.9 % of 
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patients had at least one PIM at the moment of their admission to the hospital (78). In the 
study conducted in Clinical Hospital Center Osijek, the prevalence of potential DDIs was also 
determined. It resulted that 32.8 % of the patients had at least one potential DDI (78). The 
prevalence determined in our study (49 %) was notably higher than that. 
The other study was conducted in Clinical Hospital Center Rijeka in 2013 (27). The purpose 
was to analyze pharmacotherapy of geriatric outpatients from Primorsko-Goranska County, 
who received five or more different concomitant medications. The prevalence of PIMs was 
estimated using the comprehensive protocol based on the Beers criteria, which was developed 
in 2012 by authors Mimica-Matanović and Vlahović-Palčevski (27). It was shown that 62.4 % 
of patients received at least one PIM, which is very close to our result (61 %).  
 
We have to take into consideration that the comparison studies were all conducted before the 
latest update of Beers criteria. With every update there are more PIMs which may be one 
among the reasons why our patients have higher prevalence of PIMs.  
In general, comparing the results with other studies suggests that the prevalence of both PIMs 
and DDIs in our patients was high. However, all the detected DDIs and PIMs in our patients 
are only potential and not necessarily actually harmful. The drugs that are classified as the 
inappropriate for the elderly are not considered absolutely contraindicated. Prescribing them 
requires great caution and demand to think over safer alternatives. Actual appropriateness of 
drug depends on the individual estimation of each patient. 
 
4.4. STUDY LIMITATIONS 
One potential obstacle was patients` medication list credibility. Even though the system of 
medication prescribing in Croatia is computerized and by that facilitated for many clinicians, it 
can also be misleading. Some clinicians, when dealing with older patients that are incapable of 
remembering their chronic medications at the moment of their hospitalization, use the last 
updated list of prescribed medications from the computer system. These data were also the 
ones that we were using in our study. Although potentially outdated, these were the only 
available data of our patients` medication history. Besides that, the medication adherence in 
our patients was also questionable. Since our study included geriatric patients who are often 
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prone to memory issues, we can just assume that they were taking all of their chronic systemic 
medications regularly, t.i. as prescribed, considering the fact we did not have a reliable proof 
regarding their orderliness of drug administration. 
In theory, every individual should be personally counseled in order to obtain the best possible 
medication history. To check well for each patient`s orderliness of taking prescribed 
medications, clear and concrete questions that include key words such as WHICH, HOW 
MUCH, HOW, WHY and SINCE WHEN have to be asked during counseling. This would 
help patients to understand better their chronic pharmacotherapy, but most of all it would 
enable clinicians to get the most reliable medical history, check for patients` adherence,  and 
potential drug related problems (79). That also leaded us to conclusion that prospective study 
would probably be better alternative for giving us more precise results. With such type of 
study we could obtain better insight into the each patient`s medication history since the patient 
per se would be reliable source of information. Also, in that way we could easily check on 
their adherence and correctness of taking all the prescribed chronic medications, as well as on 
the outcomes of the treatment. 
 
4.5. RECOMMENDATIONS FOR SAFER PRESCRIBING IN THE 
ELDERLY 
Our results have shown that most of the patients were exposed to high polypharmacy which 
may, among the other factors, result with numerous ADR and clinically significant DDIs. 
Almost a half of the patients (49 %) had at least one potential DDI and almost two thirds (61 
%) had at least one PIM in their chronic systemic pharmacotherapy. That leaded us to 
assumption that interaction checkers, as well as numerous criteria of prescribing in the elderly 
created with the intention to prevent inappropriate drug regimens in the older adults, are often 
disregarded. 
For reducing the incidence of clinically significant DDIs, online databases which are 
nowadays available to everybody, should always be taken into consideration, as well as 
criteria for prescribing medications in the elderly. Also, when using these sources in 
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prescribing for elderly, it would be important to consider that all detected DDIs and PIMs are 
only potential. The real risk of developing ADR due to DDIs and PIMs depends heavily on co-
morbidities, used over-the-counter preparations and life habits of every individual patient. 
Patients should also always be informed about the possible ADR they can experience when 
using drugs and they should be regularly monitored. 
Important roles in reducing the risk of ADR in elderly patients play clinical pharmacists. 
Theoretical and practical models that enable pharmacists in the community pharmacies, 
hospitals and nursing homes to take over responsibility for patients` needs and safe and 
effective pharmacotherapy, are intensively developing. In the last fifteen years, clinical 
pharmacy has been established in the most health institutions in Slovenia. In hospitals clinical 
pharmacists participate in ward rounds, run medication reconciliation at the admission and 
discharge, carry out advanced medication reviews, and introduce therapeutic drug monitoring 
of selected drugs. Advanced medication review is performed also in primary care settings by 
clinical pharmacist consultants, while medication use review is performed in the community 
pharmacies (80). 
Constantly increasing polypharmacy problem was the main reason for introduction of new 
cognitive services, t.i. medicine use review and pharmacotherapy review. The aim of these 
services is to improve safe prescribing and optimization of therapy, as well as to decrease 
financial costs (81, 82). Advanced medication review is performed by clinical pharmacist. It is 
consisted of 4 phases: collection of patients` data (using the lists of prescribed medications and 
other relevant clinical data about the patient as well as information from the patient), detection 
of drug related problems, proposal of evidence based recommendations to the physician, and 
monitoring of proposed recommendations. On the other hand, medicine use review is defined 
as a practice of collecting key information on used medications by pharmacist or clinical 
pharmacist directly from the patient himself or his guardian. The emphasis is on the patient`s 
understanding of the prescriptions he has and the correct use (81, 82). Both cognitive services 
are supposed to improve the optimization and rationalization of medication use in every 
individual patient, with the main goal of maintaining each patient`s safety and health 
correlated life quality. 
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Even though they play an important role in improving the quality of patients` care, clinical 
pharmacists are still not included in Croatian health-care practice as much as it would be 
needed. This is why community pharmacies, as a first line of healthcare, play an important 
role in patients` care. Pharmacists in the community pharmacy should tend to apply 
pharmaceutical care and intervent if detect a drug related problem or non-adherence. The use 
of medication cards is also one important factor that pharmacists should encourage and by that 
help controlling the adherence of patients. Hopefully, in the future clinical pharmacists will be 
integrated in the Croatian health institutions, which will certainly contribute to optimization of 
individual pharmacotherapies and by that reduce risk of potential ADR, as well as DDIs and 
PIMs.  
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5. CONCLUSION 
We retrospectively determined the prevalence of potential clinically significant drug-drug 
interactions and potentially inappropriate prescribed medications among elderly who were 
treated at the Department of Cardiology in Pula General Hospital and who had at least 2 
chronic systemic medications prescribed at the moment of their admission to the hospital. 
 From the total of 100 patients, 57 of them were women. Average age of the patient was 
78.2 years (range 65 – 94 years). 
 The most common reasons for hospitalization were chest pain (19 %) and dyspnea (19 
%). 
 The median number of chronic diagnoses was 4 per patient. The most common chronic 
diagnoses were arterial hypertension (67 %) and diabetes mellitus type 2 (46 %). 
 The median number of medications used per patient was 7, which is considered as high 
polypharmacy. The number of prescription medications was decreasing with the 
increasing age of the patients. 
 60 % of patients were having more than 5 concomitantly prescribed chronic systemic 
medications. 
 Most frequently prescribed medications were from the ATC classification groups C, A 
and N. Three most often used chronic systemic prescription medications were 
furosemide, pantoprazole and bisoprolol. 
 With the Lexi-Interact Online™ database we determined that 49 % of patients were 
exposed to at least one potential DDI. The median number of potential DDIs per 
patient was 2 considering the patients with detected potential DDIs. 
 The number of potential DDIs per patient was increasing with the increasing number 
of used medications. 
 Potential DDIs of only type D were detected in 38 patients. Drug combinations 
triggering DDIs of only type X were found in 3 patients. The combination of both 
categories of drug-drug interactions was present at 8 patients. 
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 Drugs most commonly involved in potential DDIs of type D were clopidogrel, 
warfarin and allopurinol. Most frequent potential DDI of type D was the one between 
clopidogrel and pantoprazole. 
 The most common potential DDIs of type X were between potassium salts, followed 
by interaction between anticholinergics (ipratropium bromide, tiotropium bromide and 
aclidinium bromide) and antipsychotics (quetiapine, promazine). 
 61 % of the patients had at least one PIM in their regular therapy, determined with 
Beers criteria. Number of PIMs per patient grew with the increasing number of 
prescribed medications. 
 Most of the PIMs in our patients belonged to the ATC classification groups A and N. 
Most frequent PIMs were pantoprazole, diazepam and amiodarone. 
 Constantly increasing polypharmacy and subsequent potential DDIs and PIMs in the 
elderly prove that clinical pharmacists are necessary. By introducing new cognitive 
services such as medicine use review and advanced medication review, optimization of 
pharmacotherapy in the elderly, as well as financial costs, would be improved. 
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7. APPENDICES 
7.1. APPENDIX A: The list of all prescribed medications in our patients. 
ORDINAL 
NO. ACTIVE SUBSTANCES 
ATC 
CLASSIFICATION 
NO. OF 
PRESCRIPTIONS 
1 acenocoumarol   B01AA07 3 
2 acetylsalicylic acid  B01AC06 26 
3 clodrnic acid  M05BA02 1 
4 folic acid  B03BB01 2 
5 
aclidinium bromide/formoterol 
fumarate dihydrate R03AL05 1 
6 allopurinol M04AA01 11 
7 
alogliptin benzoate/metformin 
hydrochloride A10BD13 1 
8 alprazolam N05BA12 7 
9 amiodarone C01BD01 14 
10 amitriptyline N06AA09 1 
11 amlodipine C08CA01 3 
12 
amlodipine 
besylate/valsartan/hydrochlorothiazid
e C09DXX01 2 
13 amlodipine/valsartan C09DB01 1 
14 anastrozole L02BG03 1 
15 apixaban B01AF02 3 
16 atenolol C07AB03 1 
17 atorvastatine C10AA05 29 
18 bilastine R06AX29 1 
19 bisoprolol C07AB07 31 
20 budesonide/formoterole R03AK07 2 
21 buprenorphine N07BC01 1 
22 calcitriol A11CC04 2 
23 carvedilol C07AG02 16 
24 chlortalidone C03BA04 1 
25 ciclesonide R03BA08 1 
26 cinnarizine N07CA02 1 
27 clopidogrel B01AC04 8 
28 clopidogrelu hydrogen sulphate B01AC-04 1 
29 cyproterone G03HA01 2 
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7.1. APPENDIX A: The list of all prescribed medications in our patients. 
(cont.) 
ORDINAL 
NO. ACTIVE SUBSTANCES 
ATC 
CLASSIFICATION 
NO. OF 
PRESCRIPTIONS 
30 dabigatran etexilate mesylate B01AE07 3 
31 desloratadine R06AX27 2 
32 dexketoprofen M01AE17 1 
33 diazepam N05BA01 17 
34 dorzolamide/timolol S01ED51 2 
35 doxazosine C02CA04 2 
36 
dutasteride/tamsulosin 
hydrochloride G04CA52 1 
37 enalapril C09AA02 2 
38 escitalopram N06AB10 2 
39 esomeprazol A02BC05 3 
40 ezetimibe C10AX09 1 
41 fenofibrate C10AB05 2 
42 finasteride G04CB01 3 
43 fluvastatine C10AA04 1 
44 fluvoxamine N06AB08 2 
45 furosemide  C03CA01 62 
46 gabapentine N03AX12 1 
47 gliclazide A10BB09 7 
48 glimepiride A10BB12 3 
49 gliquidone A10BB08 5 
50 glyceryl trinitrate solution C01DA02 5 
51 hydrocortisone H02AB09 1 
52 ibuprofen M01AE01 1 
53 indacaterol maleate R03AC18 1 
54 indapamide C03BA11 1 
55 insulin aspart A10AB05 14 
56 insulin detemir A10AE05 9 
57 insulin lispro A10AB04 2 
58 insulin glargine A10AE04 6 
59 ipratropium bromide A10AB05 2 
60 isosorbide dinitrate C01DA08 9 
61 isosorbide mononitrate C01DA14 11 
cont.=continued 
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7.1. APPENDIX A: The list of all prescribed medications in our patients. 
(cont.) 
ORDINAL 
NO. ACTIVE SUBSTANCES 
ATC 
CLASSIFICATION 
NO. OF 
PRESCRIPTIONS 
62 potassium chloride A12BA01 29 
63 
potassum citrate, potassium 
hydrogen carbonate, citric acid A12BA30 12 
64 lacidipine C08CA09 4 
65 latanoprost/timolol S01ED51 1 
66 lercanidipine C08CA13 4 
67 levothyroxine sodium H033AA01 16 
68 linagliptin A10BH05 5 
69 linagliptin/metformin A10BD11 3 
70 lisinopril C09AA03 3 
71 lisinopril/hydrochlorothiazide C09BA03 5 
72 loratadine R06AX13 1 
73 lorazepam NO5BA06 1 
74 losartan/hydrochlorothiazide C09DA01 3 
75 megestrol L02AB01 1 
76 metformin A10BA02 15 
77 metformin/glibenclamide A10BD02 1 
78 methotrexate L04AX03 1 
79 methylphenobarbital N03AA01 1 
80 methylprednisolone H02AB04 3 
81 methyldigoxin C01AA08 9 
82 metoprolol C07AB02 1 
83 montelukast R03DC03 1 
84 moxonidine C02AC05 1 
85 nebivolol C07AB12 11 
86 nitrazepam N05CD02 2 
87 omega-3 acido ethyl ester C10AX06 8 
88 oxazepam N05BA04 4 
89 oxcarbazepine N03AF02 2 
90 oxicodone/naloxone N02AA55 1 
91 pantoprazole A02BC02 32 
92 paroxetine N06AB05 2 
93 pentoxifylline C04AD03 2 
94 perindopril C09AA04 7 
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7.1. APPENDIX A: The list of all prescribed medications in our patients. 
(cont.) 
ORDINAL 
NO. ACTIVE SUBSTANCES 
ATC 
CLASSIFICATION 
NO. OF 
PRESCRIPTIONS 
95 perindopril arginine C09AA04 2 
96 perindopril arginine/amlodipine C09BB04 3 
97 perindopril/amlodipine C09BB04 2 
98 perindopril/indapamide C09BB04 2 
99 perindopril/indapamide/amlodipine C09BX01 1 
100 phenobarbital N03AA02 1 
101 
pramipexol dihydrochloride 
monohydrate N04BC05 1 
102 promazine N05AA03 1 
103 propafenone  C01BC03 2 
104 quetiapine N05AH04 1 
105 rabeprazole A02BC04 6 
106 ramipril C09AA05 7 
107 ramipril/hydrochlorothiazide C09BA05 4 
108 ranitidine A02BA02 1 
109 ranolazine C01EB18 2 
110 repaglinide A10BX02 1 
111 rivaroxaban  B01AF01 3 
112 rosuvastatin C10AA07 5 
113 salbutamol R03AC02 1 
114 salmeterol/fluticasone  R03AK06 1 
115 sertraline N06AB06 2 
116 silodosin G04CA04 1 
117 simvastatin C10AA01 7 
118 sotalol C07AA07 1 
119 spironolactone C03DA01 9 
120 tamsulosin G04CA02 6 
121 telmisartan C09CA07 5 
122 theophylline R03DA04 4 
123 thiamazol H03BB02 3 
124 tianeptine N06AX14 2 
125 ticagrelor B01AC24 1 
126 timolol S01ED01 1 
127 tiotropium bromide R03BB04 3 
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7.1. APPENDIX A: The list of all prescribed medications in our patients. 
(cont.) 
ORDINAL 
NO. ACTIVE SUBSTANCES 
ATC 
CLASSIFICATION 
NO. OF 
PRESCRIPTIONS 
128 torasemide C03CA04 9 
129 tramadol N02AX02 2 
130 tramadol/paracetamol N02AX52 10 
131 trandolapril C09AA10 8 
132 trazodone N06AX05 1 
133 trimetazidine C01EB15 15 
134 valsartan C09CA03 2 
135 valsartan/hydrochlorothiazide C09DA03 3 
136 verapamil C08DA01 1 
137 verapamil/trandolapril C08DA51 1 
138 vildagliptin A10BH02 5 
139 warfarin B01AA03 25 
140 zofenopril C09AA15 3 
141 zolpidem N05CF02 4 
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7.2. APPENDIX B: The list of all the detected drug-drug interactions of type 
D. 
POTENTIAL DRUG-DRUG INTERACTION OF TYPE D 
NO. OF 
INTERACTIONS 
gliclazide - linagliptin 1 
warfarin - allopurinol 5 
zolpidem - diazepam 1 
gliclazide – vildagliptin  2 
warfarin – amiodarone  3 
oxazepam - theophylline 1 
spironolactone - potassium chloride 3 
clopidogrel - pantoprazole 7 
repaglinide – clopidogrel 1 
zolpidem - alprazolam 2 
dorzolamide/timolol – acetylsalicylic acid  2 
amiodarone - paroxetine 1 
furosemide - methotrexate 1 
acetylsalicylic acid - methotrexate 1 
acetylsalicylic acid - ticagrelor 1 
diazepam - tramadol/paracetamol  3 
allopurinol - lisinopril 1 
allopurinol - ramipril/hydrochlorothiazide 1 
dabigatran etexilate mesylate - amiodarone 2 
glimepiride - vildagliptin 1 
simvastatin - amlodipine 1 
simvastatin - cyproterone 1 
allopurinol - trandolapril 1 
warfarin - cyproterone 1 
insulin aspart - linagliptin/metformin  2 
insulin detemir  - linagliptin/metformin 2 
loratadine - tramadol/paracetamol 1 
 nebivolol - moxonidine 1 
potassium chloride - trandolapril 1 
trandolapril - spironolactone 1 
simvastatin - lercanidipine 1 
acenocoumrol - allopurinol 2 
allopurinol - ramipril 1 
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7.2. APPENDIX B: The list of all the detected drug-drug interactions of type 
D. (cont.) 
POTENTIAL DRUG-DRUG INTERACTION OF TYPE D 
NO. OF 
INTERACTIONS 
simvastatin - perindopril arginine/amlodipine 1 
furosemide - dexketoprofen 1 
potassum citrate - perindopril 1 
oxycodone - diazepam 1 
oxycodone - lorazepam 1 
atorvastatin - phenobarbital 1 
escitalopram - phenobarbital 1 
phenobarbital - isosorbide mononitrate 1 
phenobarbital - isosorbide dinitrate 1 
oxcarbazepin - phenobarbital 1 
tramadol/paracetamol - cinnarizine 1 
tramadol/paracetamol - methylphenobarbital 1 
tramadol/paracetamol - promazine 1 
tramadol/paracetamol - quetiapine 1 
tramadol/paracetamol - tramadol 1 
quetiapine - methylphenobarbital 1 
theophylline - methylphenobarbital 1 
theophylline - carvedilol 1 
tramadol - cinnarizine 1 
tramadol - methylphenobarbital 1 
tramadol - promazine 1 
tramadol - quetiapine 1 
warfarin - methylphenobarbital 1 
clopidogrel - warfarin 1 
diazepam - phenobarbital 1 
torasemide - phenobarbital 1 
clopidogrel - rabeprazole 2 
insulin detemir  - alogliptin benzoate/metformin hydrochloride 1 
insulin lispro - alogliptin benzoate/metformin hydrochloride 1 
tramadol - alprazolam 1 
zolpidem - tramadol 1 
insulin aspart - vildagliptin 1 
insulin detemir - vildagliptin 1 
cont.=continued 
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7.2. APPENDIX B: The list of all the detected drug-drug interactions of type 
D. (cont.) 
POTENTIAL DRUG-DRUG INTERACTION OF TYPE D 
NO. OF 
INTERACTIONS 
atorvastatin - fenofibrate 2 
nitrazepam - tramadol/paracetamol 1 
perindopril arginine/amlodipine - allopurinol 1 
acenocoumarol - thiamazol 1 
diazepam - theophylline 1 
apixaban - clopidogrel 1 
alprazolam - buprenorphine 1 
alprazolam - tramadol/paracetamol 1 
perindopril/indapamide/amlodipine - amiodarone 1 
warfarin - ibuprofen 1 
acenocoumarol - amiodarone 1 
acenocoumarol - fenofibrate 1 
amiodarone - furosemide 1 
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